

AKSA AKRİLİK KİMYA SANAYİİ A.Ş.

**CONVENIENCE TRANSLATION INTO ENGLISH OF
CONSOLIDATED FINANCIAL STATEMENTS
AT 31 DECEMBER 2011 TOGETHER WITH
INDEPENDENT AUDITOR'S REPORT**

(ORIGINALLY ISSUED IN TURKISH)



**CONVENIENCE TRANSLATION INTO ENGLISH OF
INDEPENDENT AUDITOR'S REPORT
ORIGINALLY ISSUED IN TURKISH**

INDEPENDENT AUDITOR'S REPORT

To the Board of Directors of Aksa Akrilik Kimya Sanayii A.Ş.

1. We have audited the accompanying consolidated financial statements of Aksa Akrilik Kimya Sanayii A.Ş. ("Aksa") and its subsidiaries (collectively referred as the "Group") which comprise the consolidated balance sheet as of 31 December 2011 and the consolidated statement of income, consolidated statement of comprehensive income, consolidated statement of cash flows and consolidated statement of changes in equity for the year then ended and a summary of significant accounting policies and other explanatory notes.

Management's Responsibility for the Financial Statements

2. Management is responsible for the preparation and fair presentation of these consolidated financial statements in accordance with the financial reporting standards issued by the Capital Markets Board ("CMB"). This responsibility includes: designing, implementing and maintaining internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error; selecting and applying appropriate accounting policies; and making accounting estimates that are reasonable in the circumstances.

Auditor's responsibility

3. Our responsibility is to express an opinion on these consolidated financial statements based on our audit. We conducted our audit in accordance with the auditing standards issued by the CMB. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance whether the consolidated financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the Group's preparation and fair presentation of the consolidated financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Group's internal control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.



Opinion

4. In our opinion the accompanying consolidated financial statements present fairly, in all material respects, the financial position of Aksa Akrilik Kimya Sanayii A.Ş. as of 31 December 2011, and their financial performance and their cash flows for the year then ended in accordance with the financial reporting standards issued by the CMB (Note 2).

Additional Paragraph for Convenience Translation into English

5. The financial reporting standards issued by the CMB, as described in Note 2 to the accompanying consolidated financial statements, differ from International Financial Reporting Standards (“IFRS”) issued by the International Accounting Standards Board with respect to the application of inflation accounting for the period between 1 January - 31 December 2005. Accordingly, the accompanying consolidated financial statements are not intended to present the consolidated financial position, the consolidated financial performance and the consolidated cash flows of the Group in accordance with IFRS.

Başaran Nas Bağımsız Denetim ve
Serbest Muhasebeci Mali Müşavirlik A.Ş.
a member of
PricewaterhouseCoopers

A handwritten signature in blue ink, consisting of a series of loops and flourishes, positioned below the printed name.

Cansen Başaran Symes, SMMM
Partner

Istanbul, 23 March 2012

AKSA AKRİLİK KİMYA SANAYİİ A.Ş.

CONSOLIDATED FINANCIAL STATEMENTS AT 31 DECEMBER 2011

(Amounts are expressed in thousands of Turkish Lira (“TL”) unless otherwise indicated.)

CONTENTS	PAGE
CONSOLIDATED BALANCE SHEETS	1-2
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME	3
CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY	4
CONSOLIDATED STATEMENTS OF CASH FLOWS	5
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS.....	6-57
NOTE 1 ORGANISATION AND NATURE OF OPERATIONS.....	6
NOTE 2 BASIS OF PRESENTATION OF FINANCIAL STATEMENTS	7-22
NOTE 3 SEGMENT REPORTING.....	22-25
NOTE 4 CASH AND CASH EQUIVALENTS.....	25-26
NOTE 5 FINANCIAL INVESTMENTS	26
NOTE 6 FINANCIAL LIABILITIES.....	27-28
NOTE 7 TRADE RECEIVABLES AND PAYABLES	28-29
NOTE 8 OTHER RECEIVABLES AND PAYABLES	30
NOTE 9 INVENTORIES	30
NOTE 10 PROPERTY, PLANT AND EQUIPMENT	31-32
NOTE 11 INTANGIBLE ASSETS	33-34
NOTE 12 GOODWILL	34
NOTE 13 PROVISIONS, CONTINGENT ASSETS AND LIABILITIES.....	34-35
NOTE 14 EMPLOYMENT BENEFITS.....	35-36
NOTE 15 OTHER ASSETS AND LIABILITIES	36-37
NOTE 16 DERIVATIVE FINANCIAL INSTRUMENTS.....	37-38
NOTE 17 EQUITY	38-40
NOTE 18 REVENUE AND COST OF SALES	41
NOTE 19 EXPENSES BY NATURE.....	41
NOTE 20 OTHER OPERATING INCOME AND EXPENSE.....	41
NOTE 21 FINANCIAL INCOME.....	42
NOTE 22 FINANCIAL EXPENSE.....	42
NOTE 23 TAX ASSETS AND LIABILITIES	42-44
NOTE 24 EARNINGS PER SHARE	44
NOTE 25 TRANSACTIONS AND BALANCES WITH RELATED PARTIES	44-46
NOTE 26 FINANCIAL RISK MANAGEMENT	46-55
NOTE 27 FINANCIAL INSTRUMENTS.....	55-56
NOTE 28 OTHER ISSUES THAT SIGNIFICANTLY EFFECT THE FINANCIAL STATEMENTS OR OTHER ISSUES REQUIRED FOR THE CLEAR UNDERSTANDING OF FINANCIAL STATEMENTS AND SUBSEQUENT EVENTS	57

**CONVENIENCE TRANSLATION INTO ENGLISH OF CONSOLIDATED
FINANCIAL STATEMENTS ORIGINALLY ISSUED IN TURKISH (NOTE 2.5)**

AKSA AKRİLİK KİMYA SANAYİİ A.Ş.

CONSOLIDATED BALANCE SHEETS AT 31 DECEMBER 2011 AND 2010

(Amounts expressed in thousands of Turkish Lira ("TL") unless otherwise indicated.)

		31 December 2011 USD	31 December 2011 TL	31 December 2010 TL
	Notes			
ASSETS				
Current Assets				
		406.678	768.174	664.328
Cash and cash equivalents	4	45.056	85.106	64.499
Trade receivables				
- Other trade receivables	7	141.068	266.464	307.143
- Due from related parties	25	71.381	134.832	16.349
Other receivables	8	118	223	36.918
Inventories	9	101.316	191.375	159.496
Other current assets	15	47.739	90.174	79.923
Non-current assets				
		468.204	884.391	694.574
Trade receivables	7	569	1.074	9.553
Financial investments	5	733	1.385	8.008
Property, plant and equipment	10	444.129	838.915	658.942
Intangible assets	11	11.333	21.406	5.175
Goodwill	12	3.171	5.989	5.989
Other non-current assets	15	8.270	15.622	6.907
TOTAL ASSETS				
		874.882	1.652.565	1.358.902

These consolidated financial statements at 31 December 2011 have been approved for issue by the Board of Directors on 23 March 2012 and signed on behalf of the Board of Directors by Cengiz Taş, General Manager and by Mustafa Yılmaz, member of the Board of Directors. These consolidated financial statements will be definitive following their approval in the General Assembly.

The accompanying notes form an integral part of these consolidated financial statements.

**CONVENIENCE TRANSLATION INTO ENGLISH OF CONSOLIDATED
FINANCIAL STATEMENTS ORIGINALLY ISSUED IN TURKISH (NOTE 2.5)**

AKSA AKRİLİK KİMYA SANAYİİ A.Ş.

CONSOLIDATED BALANCE SHEETS AT 31 DECEMBER 2011 AND 2010

(Amounts expressed in thousands of Turkish Lira ("TL") unless otherwise indicated.)

	Notes	31 December 2011 USD)	31 December 2011 TL	31 December 2010 TL
LIABILITIES				
Current liabilities		229.220	432.974	398.730
Financial liability	6	91.580	172.986	171.258
Trade payables				
- Other trade payables	7	119.718	226.135	175.294
- Due to related parties	25	14.097	26.628	36.429
Other payables	8	1.097	2.072	3.808
Taxes on income	23	195	369	3.839
Provisions	13	1.734	3.276	2.237
Other current liabilities	15	798	1.508	5.865
Non-current liabilities		195.163	368.644	184.407
Financial liabilities	6	169.540	320.245	139.307
Derivative financial instruments	16	2.210	4.175	5.000
Provision for employee termination benefits	14	7.528	14.220	13.168
Deferred income tax liabilities	23	9.096	17.182	13.463
Other non-current liabilities	15	6.788	12.822	13.469
Total liabilities		424.384	801.618	583.137
EQUITY		450.499	850.947	775.765
Attributable to equity holders of the parent		445.460	841.429	757.988
Share capital	17	97.941	185.000	185.000
Adjustment to share capital	17	103.327	195.175	195.175
Share premium		23	44	44
Restricted reserves		27.816	52.542	48.523
Currency translation differences		627	1.185	-
Hedge funds		(1.768)	(3.340)	(4.000)
Retained earnings		166.115	313.774	276.528
Net income for the period		51.379	97.049	56.718
Non-controlling interests		5.039	9.518	17.777
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY		874.882	1.652.565	1.358.902

The accompanying notes form an integral part of these consolidated financial statements.

**CONVENIENCE TRANSLATION INTO ENGLISH OF CONSOLIDATED
FINANCIAL STATEMENTS ORIGINALLY ISSUED IN TURKISH (NOTE 2.5)**

AKSA AKRİLİK KİMYA SANAYİİ A.Ş.

**CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
FOR THE YEARS ENDED 31 DECEMBER 2011 AND 2010**

(Amounts expressed in thousands of Turkish Lira ("TL") unless otherwise indicated.)

	Notes	31 December 2011 USD	31 December 2011 TL	31 December 2010 TL
Continuing operations				
Sales	18	887.008	1.675.470	1.304.312
Cost of sales (-)	18,19	(763.551)	(1.442.272)	(1.142.683)
Gross profit		123.457	233.198	161.629
Marketing, selling and distribution expenses (-)	19	(16.338)	(30.860)	(21.206)
General administrative expenses (-)	19	(28.282)	(53.422)	(56.177)
Research and development expenses (-)	19	(1.425)	(2.692)	(3.287)
Other operating income	20	5.882)	11.111	4.798
Other operating expenses (-)	20	(8.027)	(15.163)	(4.865)
Operating profit		75.267	142.172	80.892
Financial income	21	81.547	154.035	120.805
Financial expenses (-)	22	(92.371)	(174.479)	(125.927)
Profit before tax		64.444	121.728	75.770
Taxation expense on income				
- Income tax expense	23	(9.951)	(18.796)	(14.813)
- Deferred tax (charge)/benefit	23	(1.834)	(3.465)	957
Net income for the year		52.659	99.467	61.914
Other comprehensive (expense)/income:				
Changes in fair value of derivative financial instruments		349	660	(971)
Currency translation differences		627	1.185	-
Total comprehensive income		53.635	101.312	60.943
Net income for the year attributable to				
Equity holders of the parent		51.379	97.049	56.718
Non-controlling interests		1.280	2.418	5.196
		52.659	99.467	61.914
Total comprehensive year attributable to:				
Equity holders of the parent		52.355	98.894	55.747
Non-controlling interests		1.280	2.418	5.196
		53.635	101.312	60.943
Earnings per share for equity holders of the parent (Kr)	24	0,28	0,52	0,31

The accompanying notes form an integral part of these consolidated financial statements.

CONVENIENCE TRANSLATION INTO ENGLISH OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN TURKISH (NOTE 2.5)

AKSA AKRİLİK KİMYA SANAYİİ A.Ş.

CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY FOR THE YEARS ENDED 31 DECEMBER 2011 AND 2010

(Amounts expressed in thousands of Turkish Lira ("TL") unless otherwise indicated.)

	Attributable to equity holders of the parent										Non-controlling interests	Total shareholder's equity
	Share Capital	Adjustments to share Capital	Share Premium	Restricted Reserves	Currency translation differences	Hedge Reserve	Retained Earnings	Net income for the period	Total			
Balances at 1 January 2010	185.000	195.175	44	45.866	-	(3.029)	256.754	39.984	719.794	14.589	734.383	
Transfers	-	-	-	2.657	-	-	37.327	(39.984)	-	-	-	
Dividends paid	-	-	-	-	-	-	(17.553)	-	(17.553)	(2.008)	(19.561)	
Total comprehensive income	-	-	-	-	-	(971)	-	56.718	55.747	5.196	60.943	
Balances at 31 December 2010	185.000	195.175	44	48.523	-	(4.000)	276.528	56.718	757.988	17.777	775.765	

	Attributable to equity holders of the parent										Non-controlling interests	Total shareholder's equity
	Share Capital	Adjustments to share Capital	Share Premium	Restricted Reserves	Currency translation differences	Hedge Reserve	Retained Earnings	Net income for the period	Total			
Balances at 1 January 2011	185.000	195.175	44	48.523	-	(4.000)	276.528	56.718	757.988	17.777	775.765	
Transfers	-	-	-	4.019	-	-	52.699	(56.718)	-	-	-	
Change in the scope of consolidation (Note 2.1.3)	-	-	-	-	-	-	2.025	-	2.025	(9.283)	(7.258)	
Dividends paid	-	-	-	-	-	-	(17.478)	-	(17.478)	(1.394)	(18.872)	
Total comprehensive income	-	-	-	-	1.185	660	-	97.049	98.894	2.418	101.312	
Balances at 31 December 2011	185.000	195.175	44	52.542	1.185	(3.340)	313.774	97.049	841.429	9.518	850.947	

The accompanying notes form an integral part of these consolidated financial statements.

**CONVENIENCE TRANSLATION INTO ENGLISH OF CONSOLIDATED
FINANCIAL STATEMENTS ORIGINALLY ISSUED IN TURKISH (NOTE 2.5)**

AKSA AKRİLİK KİMYA SANAYİİ A.Ş.

**CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE YEARS ENDED
31 DECEMBER 2011 AND 2010**

(Amounts expressed in thousands of Turkish Lira ("TL") unless otherwise indicated.)

	Notes	31 December 2011 USD	31 December 2011 TL	31 December 2010 TL
Profit before tax		64.444	121.728	75.770
Adjustments to reconcile income before tax to net cash generated from operating activities:				
Depreciation and amortisation	19	24.667	46.594	54.643
Provision for employment termination benefits		1.902	3.593	3.216
Interest income	21	(11.214)	(21.182)	(24.145)
Interest expense	22	9.475	17.898	18.760
Income from government grants		(801)	(1.513)	(1.344)
Provision cancellation income for impairment on inventory		(1.434)	(2.709)	(2.974)
Provision for impairment on trade receivables	7	6.158	11.632	2.977
Unrealized exchange differences		25.998	49.107	7.032
Other		(448)	(846)	554
Cash flows before changes in operating assets and liabilities		118.747	224.302	134.489
Changes in operating assets and liabilities:				
Taxes paid		508	960	809
Changes in restricted cash		(469)	(886)	(8)
Changes in trade receivables		(38.637)	(72.981)	13.417
Changes in other receivables		(33)	(62)	(26.010)
Changes in inventories		(23.550)	(44.483)	(40.681)
Changes in other receivables		(21.830)	(41.234)	3.836
Changes in trade payables		25.175	47.554	41.047
Changes in other payables		(745)	(1.408)	(816)
Changes in other liabilities		4.071	7.689	(5.619)
Employment termination benefits paid	14	(1.149)	(2.170)	(1.568)
Net cash provided from operating activities		62.090	117.281	118.896
Investing activities:				
Purchase of property, plant and equipment		(130.063)	(245.676)	(166.109)
Proceeds from sale of property, plant and equipment		185	350	70
Interest received		11.175	21.108	23.132
Net cash used in investing activities		(118.703)	(224.218)	(142.907)
Financing activities:				
Investment loans received		104.669	197.710	54.856
Investment loans paid		(26.206)	(49.500)	(46.054)
Changes in revolving bank loans, net		13.627	25.740	14.055
Dividends paid to equity holders of the parent		(9.253)	(17.478)	(17.553)
Dividends paid to non-controlling interests		(738)	(1.394)	(2.008)
Changes in non-controlling interests		(4.915)	(9.283)	-
Interest paid		(10.156)	(19.184)	(16.940)
Net cash provided/ (used in) financing activities		67.029	126.611	(13.644)
Net increase/ (decrease) in cash and cash equivalents		10.416	19.674	(37.655)
Cash and cash equivalents at 1 January	4	33.891	64.017	101.672
Cash and cash equivalents at 31 December	4	44.307	83.691	64.017

The accompanying notes form an integral part of these consolidated financial statements.

CONVENIENCE TRANSLATION INTO ENGLISH OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN TURKISH (NOTE 2.5)

AKSA AKRİLİK KİMYA SANAYİİ A.Ş.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2011

(Amounts expressed in thousands of Turkish Lira (“TL”) unless otherwise indicated.)

NOTE 1 - ORGANISATION AND NATURE OF OPERATIONS

Aksa Akrilik Kimya Sanayii A.Ş. (“Aksa” or the “Company”) was established on 9 October 1968 and registered in Turkey.

The Company is mainly engaged in the manufacturing, importing, exporting, marketing and trading of the products and raw materials, supplementary materials and intermediary materials used in textile, chemicals and other industries, and artificial, synthetic, natural fibers, filaments and polymers, and the machinery, equipment, and spare parts used in their production, processing and storage. In addition, the Company engaged in establishing electricity production center, operating and producing the electricity.

Aksa is registered with the Capital Markets Board (“CMB”) and its shares have been quoted in the Istanbul Stock Exchange (“ISE”) since 1986.

As of 31 December 2011, the principle shareholders and their respective shareholding rates in the Company are as follows (Note 17):

	%
Akkök Sanayi Yatırım ve Geliştirme A.Ş. (“Akkök”)	39,59
Emniyet Ticaret ve Sanayi A.Ş.	18,72
Other (*)	41,69
Total	100,00

(*) As of 31 December 2011, %37,63 of the Group’s shares is traded on ISE.

The address of the registered office of the Company is as follows:

Miralay Şefik Bey Sokak
No: 15 Akhan
Gümüşsuyu 34437 İstanbul

Subsidiaries

The Company has the following subsidiaries (the “Subsidiaries”). The nature of the business of the Subsidiaries and their country of operations are as follows.

Subsidiaries	Country	Nature of business
Ak-Tops Tekstil Sanayi A.Ş. (“Ak-Tops”)	Turkey	Textile
Fitco BV (“Fitco”)	Holland	Investment
Aksa Egypt Acrylic Fiber Industry SAE (“Aksa Egypt”)	Egypt	Textile
Akgirişim Kimya ve Ticaret A.Ş. (“Akgirişim”)	Turkey	Chemical

Main operations of the Group are in Turkey and for the purpose of segment reporting, the operations are summarized in three operational segments as fibers, energy and other (Note 3).

**CONVENIENCE TRANSLATION INTO ENGLISH OF CONSOLIDATED
FINANCIAL STATEMENTS ORIGINALLY ISSUED IN TURKISH (NOTE 2.5)**

AKSA AKRİLİK KİMYA SANAYİİ A.Ş.

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2011**

(Amounts expressed in thousands of Turkish Lira (“TL”) unless otherwise indicated.)

NOTE 2 - BASIS OF PRESENTATION OF FINANCIAL STATEMENTS

2.1 Basis of preparation

2.1.1 Financial Reporting Standards Applied

The consolidated financial statements of Aksa have been prepared in accordance with the accounting and reporting principles accepted by the Capital Markets Board (“CMB”), namely “CMB Financial Reporting Standards”. CMB regulated the principles and procedures of preparation, presentation and announcement of financial statements prepared by the entities with the Communiqué No: XI-29, “Principles of Financial Reporting in Capital Markets” (“the Communiqué”). According to the Communiqué, entities shall prepare their financial statements in accordance with International Financial Reporting Standards (“IAS/IFRS”) endorsed by the European Union. Until the differences of the IAS/IFRS as endorsed by the European Union from the ones issued by the International Accounting Standards Board (“IASB”) are announced by Turkish Accounting Standards Board (“TASB”), IAS/IFRS issued by the IASB shall be applied. Accordingly, Turkish Accounting Standards/Turkish Financial Reporting Standards (“TAS/TFRS”) accepted by the TASB which are in line with the aforementioned standards shall be considered.

With the decision taken on 17 March 2005, the CMB announced that, effective from 1 January 2005, for companies operating in Turkey and preparing their financial statements in accordance with CMB Financial Reporting Standards, the application of inflation accounting is no longer required. Accordingly, IAS 29, “Financial Reporting in Hyperinflationary Economies”, issued by the IASB, has not been applied in the financial statements for the accounting periods starting 1 January 2005.

As the differences of the IAS/IFRS endorsed by the European Union from the ones issued by the IASB have not been announced by TASB as of the date of preparation of these consolidated financial statements, the consolidated financial statements have been prepared within the framework of Communiqué XI, No: 29 and related promulgations to this Communiqué as issued by the CMB, in accordance with the CMB Financial Reporting Standards which are based on IAS/IFRS.

The consolidated financial statements and the related notes to them are presented in accordance with the formats recommended by the CMB, with the compulsory disclosures.

Aksa and its Subsidiaries registered in Turkey maintain their books of account and prepare their statutory financial statements in accordance with the Turkish Commercial Code (“TCC”), tax legislation and the Uniform Chart of Accounts issued by the Ministry of Finance and accounting principles issued by the CMB for listed companies. These consolidated financial statements are based on the statutory records, which are maintained under historical cost conversion, with the required adjustments and reclassifications reflected for the purpose of fair presentation in accordance with the CMB Financial Reporting Standards.

CONVENIENCE TRANSLATION INTO ENGLISH OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN TURKISH (NOTE 2.5)

AKSA AKRİLİK KİMYA SANAYİİ A.Ş.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2011

(Amounts expressed in thousands of Turkish Lira (“TL”) unless otherwise indicated.)

NOTE 2 - BASIS OF PRESENTATION OF FINANCIAL STATEMENTS (Continued)

Amendments in International Financial Reporting Standards

a) Standards, amendments and interpretations effective from 1 January 2011 and applied by Group:

- IAS 24 (revised), “Related party disclosures”, issued in November 2009. It supersedes IAS 24, “Related party disclosures”, issued in 2003. IAS 24 (revised) is mandatory for periods beginning on or after 01 January 2011. Earlier application, in whole or in part, is permitted.

- Annual improvements 2010 are effective for annual periods beginning 1 January 2011. This set of amendments includes changes to six standards and one IFRIC, namely:

IFRS 7 “Financial Instruments: Disclosures”

IAS 1 “Presentation of financial statements”

IAS 27 (Revised), “Consolidated and Separate Financial Statements”

IAS 34 “Interim Financial Reporting”

b) Amendments and interpretations effective from 1 January 2011 but not has material impact on Group’s financial statements:

- IFRIC 19, “Extinguishing financial liabilities with equity instruments”, effective 01 July 2010. The interpretation clarifies the accounting by an entity when the terms of a financial liability are renegotiated and result in the entity issuing equity instruments to a creditor of the entity to extinguish all or part of the financial liability (debt for equity swap). It requires a gain or loss to be recognised in profit or loss, which is measured as the difference between the carrying amount of the financial liability and the fair value of the equity instruments issued.

- IAS 32 (Amendment), “Financial instruments: Presentation” The amendment applies to annual periods beginning on or after 1 February 2010. The amendment addresses the accounting for rights issues that are denominated in a currency other than the functional currency of the issuer

- IFRS 1, “First time adoption of IFRS” effective 01 July 2010. Provides the same relief to first-time adopters as was given to current users of IFRSs upon adoption of the amendments to IFRS 7. Also clarifies the transition provisions of the amendments to IFRS 7.

- IFRIC 14, “Prepayments of a minimum funding requirement” effective 01 January 2011. The amendments correct an unintended consequence of IFRIC 14, ‘IAS 19 - The limit on a defined benefit asset, minimum funding requirements and their interaction’. Without the amendments, entities are not permitted to recognise as an asset some voluntary prepayments for minimum funding contributions.

- Annual improvements 2010 are effective for annual periods beginning 1 January 2011. This set of amendments includes changes to six standards and one IFRIC, namely:

IFRS 1, “First time adoption of IFRS”

IFRS 3, ‘Business combinations’

IFRIC 13, ‘Customer loyalty programmes’

CONVENIENCE TRANSLATION INTO ENGLISH OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN TURKISH (NOTE 2.5)

AKSA AKRİLİK KİMYA SANAYİİ A.Ş.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2011

(Amounts expressed in thousands of Turkish Lira (“TL”) unless otherwise indicated.)

NOTE 2 - BASIS OF PRESENTATION OF FINANCIAL STATEMENTS (Continued)

c) *Standards, amendments and interpretations to existing standards those are not yet effective in 2011:*

- IFRS 7 (Amendment), “Financial Instruments: Disclosures” effective from 1 July 2011. Emphasises the interaction between quantitative and qualitative disclosures about the nature and extent of risks associated with financial instruments.
- IFRS 1 (Amendment), “First time adoption” is effective for annual periods beginning on or after 1 July 2011. Amendment provides guidance on how an entity should resume presenting financial statements in accordance with IFRSs after a period when the entity was unable to comply with IFRSs because its functional currency was subject to severe hyperinflation.
- IAS 12 (Amendment), “Income taxes” is effective for annual periods beginning on or after 1 January 2012. This amendment introduces an exception to the existing principle for the measurement of deferred tax assets or liabilities arising on investment property measured at fair value.
- IAS 19 (Amendment), “Employee benefits” is effective for annual periods beginning on or after 1 January 2013. These amendments eliminate the corridor approach and calculate finance costs on a net funding basis.
- IAS 1 (Amendment), “Financial statement presentation” is effective for annual periods beginning on or after 1 July 2012. The main change resulting from these amendments is a requirement for entities to group items presented in Other comprehensive income (OCI) on the basis of whether they are potentially recycled to profit or loss (reclassification adjustments).
- IFRS 9, “Financial Instruments” is not applicable until 1 January 2013 but is available for early adoption. This standard is the first step in the process to replace IAS 39, “Financial instruments: recognition and Measurement”. IFRS 9 introduces new requirements for classifying and measuring financial assets.
- IFRS 10, “Consolidated financial statements” is effective for annual periods beginning on or after 1 January 2013. This standard builds on existing principles by identifying the concept of control as the determining factor in whether an entity should be included within the consolidated financial statements. The standard provides additional guidance to assist in determining control where this is difficult to assess.
- IFRS 11, “Joint arrangements” is effective for annual periods beginning on or after 1 January 2013. This standard provides for a more realistic reflection of joint arrangements by focusing on the rights and obligations of the arrangement, rather than its legal form. There are two types of joint arrangement: joint operations and joint ventures. Proportional consolidation of joint ventures is no longer allowed.
- IFRS 12, “Disclosures of interests in other entities” is effective for annual periods beginning on or after 1 January 2013. This standard includes the disclosure requirements for all forms of interests in other entities, including joint arrangements, associates, special purpose vehicles and other off balance sheet vehicles
- IFRS 13, “Fair value measurement” is effective for annual periods beginning on or after 1 January 2013. This standard aims to improve consistency and reduce complexity by providing a precise definition of fair value and a single source of fair value measurement and disclosure requirements for use across IFRS.

CONVENIENCE TRANSLATION INTO ENGLISH OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN TURKISH (NOTE 2.5)

AKSA AKRİLİK KİMYA SANAYİİ A.Ş.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2011

(Amounts expressed in thousands of Turkish Lira ("TL") unless otherwise indicated.)

NOTE 2 - BASIS OF PRESENTATION OF FINANCIAL STATEMENTS (Continued)

- IAS 27, "Separate financial statements" is effective for annual periods beginning on or after 1 January 2013. This standard includes the provisions on separate financial statements that are left after the control provisions of IAS 27 have been included in the new IFRS 10.
- IAS 28, "Associates and joint ventures" is effective for annual periods beginning on or after 1 January 2013. This standard includes the requirements for joint ventures, as well as associates, to be equity accounted following the issue of IFRS 11.

2.1.2 Functional and Presentation Currency

Items included in the financial statements of each of the Group's entities are measured using the currency of the primary economic environment in which the entity operates ('the functional currency'). The consolidated financial statements are presented in TL. The Group prepared its consolidated financial statements in accordance with the going concern assumption.

2.1.3 Basis of Consolidation

- The consolidated financial statements include the accounts of the parent company, Aksa, and its Subsidiaries on the basis set out in sections (b) below. The financial statements of the companies included in the scope of consolidation have been prepared as of the date of the consolidated financial statements and have been prepared in accordance with CMB Financial Reporting Standards by applying uniform accounting policies and presentation. The results of operations of Subsidiaries are included or excluded from their effective dates of acquisition or disposal respectively.
- Subsidiaries are companies in which Aksa has the power to control the financial and operating policies for the benefit of itself, either (1) through the power to exercise more than 50% of voting rights related to shares in the companies as a result of shares owned directly and/or indirectly by itself or (2) although not having the power to exercise more than 50% of the voting rights, through the exercise of actual dominant influence over the financial and operating policies.

The table below sets out all Subsidiaries and demonstrates their shareholding structure as of 31 December 2011 and 2010:

<u>Subsidiary</u>	Direct and indirect ownership interest by the Company and its subsidiaries (%)	
	<u>31 December 2011</u>	<u>31 December 2010</u>
Ak-Tops ⁽¹⁾	60,00	60,00
Fitco ^{(1), (3)}	100,00	100,00
Aksa Egypt ^{(1), (3)}	99,14	99,14
Akgirişim ⁽²⁾	58,00	58,00
<u>Subsidiaries</u>		
Ak-Pa ^{(2), (4)}	13,47	13,47

(1) The financial statements of subsidiaries are consolidated on a line-by-line basis.

(2) Although the Company has the power to exercise more than 50% of the voting rights, on the grounds of materiality these Subsidiaries have been classified and accounted for as financial assets in the consolidated financial statements with a carrying value of their initial acquisition costs less impairment, if any.

(3) These subsidiaries have been included in the scope of full consolidation as at the balance sheet date.

(4) As of 1 January 2011 these subsidiaries have been included in the scope of full consolidation as at the balance sheet date.

CONVENIENCE TRANSLATION INTO ENGLISH OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN TURKISH (NOTE 2.5)

AKSA AKRİLİK KİMYA SANAYİİ A.Ş.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2011

(Amounts expressed in thousands of Turkish Lira (“TL”) unless otherwise indicated.)

NOTE 2 - BASIS OF PRESENTATION OF FINANCIAL STATEMENTS (Continued)

Subsidiaries are consolidated from the date on which the control is transferred to the Group and are deconsolidated from the date that the control ceases. Where necessary, accounting policies for Subsidiaries have been changed to ensure consistency with the policies adopted by the Group.

Carrying values of the Subsidiaries’ shares held by the Company are eliminated against the related equity of Subsidiaries. Intercompany transactions and balances between Aksa and its Subsidiaries are eliminated on consolidation. Dividends arising from shares held by the Company in its Subsidiaries are eliminated from income for the period and equity, respectively.

The minority shareholders’ share in the net assets and results of Subsidiaries for the period are separately classified as non-controlling interests in the consolidated balance sheets and statements of comprehensive income.

The financial statements of the subsidiaries that are located in foreign countries, are prepared according to related countries’ regulations, the required adjustments and reclassifications reflected for the purpose of fair presentation in accordance with the CMB Financial Reporting Standards . Foreign subsidiaries’ asset and liabilities have been translated to Turkish Liras at the balance sheet date currency. Income statement has been translated to TL with the average currency. Closing and average currency translation differences have shown under currency translation differences.

Changes in the scope of consolidation:

The Company ceased to have the power to govern the operational and financial policies of Ak-Pa Tekstil İhracat Pazarlama A.Ş. The assets and consolidated value of liabilities of Ak-pa are excluded from the scope of consolidation as of 1 January 2011 and as of that date, the carrying value of Ak-Pa’s equity attributable to the participation rate of the Company is designated as the cost of the investment which approximate the fair value and included in the consolidated financial statements.

As of 1 January 2011, Akxa Egypt and Fitco, subsidiaries of the Group, have been included to full consolidation scope per their increasing importance on the grounds of materiality.

2.2 Changes in Accounting Policies, Accounting Estimates and Errors

Significant changes in accounting policies or significant errors are corrected, retrospectively; by restating the prior period consolidated financial statements. The effect of changes in accounting estimates affecting the current period is recognised in the current period; the effect of changes in accounting estimates affecting current and future periods is recognised in the current and future periods.

2.3 Summary of Significant Accounting Policies

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and at banks and short-term highly liquid investments whose risk of value change is not material including time deposits generally having original maturities of three months or less (Note 4).

CONVENIENCE TRANSLATION INTO ENGLISH OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN TURKISH (NOTE 2.5)

AKSA AKRİLİK KİMYA SANAYİİ A.Ş.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2011

(Amounts expressed in thousands of Turkish Lira (“TL”) unless otherwise indicated.)

NOTE 2 - BASIS OF PRESENTATION OF FINANCIAL STATEMENTS (Continued)

Financial Assets

Financial assets within the scope of IAS 39 are classified as financial assets at fair value through profit or loss, loans and receivables, held-to-maturity investments, or available-for-sale financial assets, as appropriate. When financial assets are recognised initially, they are measured at fair value, plus, in the case of investments not at fair value through profit or loss, directly attributable transaction costs.

The Group determines the classification of its financial assets on initial recognition and, where allowed and appropriate, re-evaluates this designation at each financial year end. All regular way purchases and sales of financial assets are recognised on the trade date, which is the date that the Group commits to purchase the asset. Regular way purchases or sales are purchases or sales of financial assets that require delivery of assets within the period generally established by regulation or convention in the marketplace.

As of 31 December 2011 and 31 December 2010 the Group does not have any financial assets at fair value through profit or loss.

Loans and Receivables

Loans and receivables are non-derivative financial assets with fixed or determinable payments that are not quoted in an active market. After initial measurement loans and receivables are carried at amortised cost using the effective interest method less any allowance for impairment. Gains and losses are recognised in profit or loss when the loans and receivables are derecognised or impaired, as well as through the amortisation process.

Available-for-sale financial assets

Available for sale financial assets are non-derivative financial assets that are designated as available for-sale or that are not classified in any of the three categories (a) loans and receivables, (b) held-to-maturity investments and (c) assets at fair value through profit or loss. A gain or loss on an available for-sale financial asset after initial recognition shall be recognized directly in equity, through the statement of changes in equity, except for impairment losses, dividend and interest gains, until the financial asset is derecognized, at which time the cumulative gain or loss previously recognized in equity shall be recognized in profit or loss. If a fair value loss on an available-for-sale asset has been recognized directly in equity, and there is objective evidence that the asset is impaired, the cumulative loss that has been recognized directly in equity should be recycled into profit or loss even though the financial asset has not been sold.

Available-for-sale financial assets are subsequently measured at fair value. Available-for-sale financial assets that are quoted in active markets are measured based on current bid prices. If the market for a financial asset is not active the fair value is determined by using valuation techniques such as discounted cash flow analysis and option pricing model (Note 5).

For investments as subsidiaries that are excluded from the scope of consolidation on the grounds of materiality where there is no quoted market price and where a reasonable estimate of fair value cannot be determined since other methods are inappropriate and unworkable, they are carried at cost less any impairment in value (Note 5).

CONVENIENCE TRANSLATION INTO ENGLISH OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN TURKISH (NOTE 2.5)

AKSA AKRİLİK KİMYA SANAYİİ A.Ş.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2011

(Amounts expressed in thousands of Turkish Lira (“TL”) unless otherwise indicated.)

NOTE 2 - BASIS OF PRESENTATION OF FINANCIAL STATEMENTS (Continued)

Trade receivables

Trade receivables have a maturity range of 30-120 days and are recognized at original invoice amount and carried at amortized cost less an allowance for any uncollectible amounts. An estimate for doubtful debt is made when collection of the full amount is no longer probable. A credit risk provision for trade receivables is established if there is objective evidence that the Group will not be able to collect all amounts due. The allowance is an estimated amount which is difference between existing receivable and collectible amount. Collectible amount is the discounted value of trade receivables, all cash flows including collections from guarantees by using original effective interest rate. Bad debts are written off when identified (Note 7).

The Group has accrued discount premiums in line with the fibers customers’ purchase targets to be paid at the end of the year. In the current period, the Group has classified the discount premiums under “other discount” account in sales.

Trade payables

Trade payables have average maturities changing between 30-180 days and consist of the amounts invoiced or not invoiced related with the realized material or service purchases, and are carried at amortized cost (Note 7).

Inventories

Inventories are valued at the lower of cost or net realisable value less costs to sell. Cost of inventories comprises the purchase cost and the cost of bringing inventories into their present location and condition. Cost is determined by the monthly moving weighted average method. The cost of borrowings is not included in the costs of inventories. Net realisable value less costs to sell is the estimated selling price in the ordinary course of business, less the estimated costs necessary to make the sale (Note 9).

Property, plant and equipment

Property, plant and equipment are stated at cost less accumulated depreciation and accumulated impairment loss. When assets are sold or retired, their costs and accumulated depreciation are eliminated from the accounts and any gain or loss resulting from their disposal is included in the income statement.

The initial cost of property, plant and equipment comprises its purchase price, including import duties and any directly attributable costs of bringing the asset to its working condition and location for its intended use.

Depreciation is provided for property, plant and equipment on a straight-line basis (Note 10). Useful life and the depreciation method are constantly reviewed, and accordingly, parallels are sought between the depreciation method and the period and the useful life to be derived from the related asset. As of 31 December 2011, the depreciation periods for property, plant and equipment, which approximate the economic useful lives of such assets, are as follows:

	Period (Years)
Land	2 - 50
Buildings	5 - 50
Machinery and equipment	3 - 40
Motor vehicles	4 - 8
Furniture and fixtures	2 - 20

CONVENIENCE TRANSLATION INTO ENGLISH OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN TURKISH (NOTE 2.5)

AKSA AKRİLİK KİMYA SANAYİİ A.Ş.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2011

(Amounts expressed in thousands of Turkish Lira ("TL") unless otherwise indicated.)

NOTE 2 - BASIS OF PRESENTATION OF FINANCIAL STATEMENTS (Continued)

The Group assesses at each balance sheet date whether there is objective evidence that a financial asset or a group of financial assets is impaired. In the event of circumstances indicating that an impairment has occurred in the tangible assets, an inspection is performed for the purpose of determining a possible impairment, and if the registered value of the tangible asset is higher than its recoverable value, the registered value is reduced to its recoverable value by reserving a provision. The recoverable value is considered either the net cash flow to be caused by the current use of the respective tangible assets or the net sales price, whichever is higher.

Gains or losses on disposals of property, plant and equipment are determined by comparing proceeds with their restated carrying amounts and are included in the related income and expense accounts, as appropriate.

Repairs and maintenance are charged to the income statements during the financial period in which they are incurred. The cost of major renovations is included in the carrying amount of the asset when it is probable that future economic benefits in excess of the originally assessed standard of performance of the existing asset.

Intangible assets

Intangible assets acquired separately from a business are capitalized at cost. Intangible assets, created within the business are not capitalized and expenditure is charged against profits in the year in which it is incurred. They are initially recognised at acquisition cost and amortised on a straight-line basis over their estimated useful lives. The depreciation period for the intangibles capitalized in relation with the new models will be started after the production of these models is started. The carrying values of intangible assets are reviewed for impairment when events or changes in circumstances indicate that the carrying value may not be recoverable (Note 11).

Useful lives of intangible assets are determined as 3-15 years.

Research and development costs

Expenditures for research and development are charged against income in the period incurred except for project development costs which comply with the following criteria:

- The product or process is clearly defined and costs are separately identified and measured reliably,
- The technical feasibility of the product is demonstrated,
- The product or process will be sold or used in-house,
- A potential market exists for the product or its usefulness in case of internal use is demonstrated, and
- Adequate technical, financial and other resources required for completion of the project are available.

The costs related to the development projects are capitalized when the criteria above are met and amortized by straight-line basis over the useful lives of related projects (Note 11).

Revenue recognition

Revenue is recognized to the extent that it is probable that the economic benefits will flow to the Group and the revenue can be reliably measured. Revenues are stated net of discounts, value added and sales taxes. Revenue is recognized when the significant risks and rewards of ownership of the goods have passed to the buyer and the amount of revenue can be measured reliably. Net sales are invoiced amounts of delivered goods excluding sales returns and sales discounts.

CONVENIENCE TRANSLATION INTO ENGLISH OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN TURKISH (NOTE 2.5)

AKSA AKRİLİK KİMYA SANAYİİ A.Ş.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2011

(Amounts expressed in thousands of Turkish Lira (“TL”) unless otherwise indicated.)

NOTE 2 - BASIS OF PRESENTATION OF FINANCIAL STATEMENTS (Continued)

Interest income is recognised using the effective interest rate until maturity and considering the effective interest rate.

When the arrangement effectively constitutes a financing transaction, the fair value of the consideration is determined by discounting all future receipts using an imputed rate of interest. The difference between the fair value and the nominal amount of the consideration is recognized on an accrual basis as credit sale financial income (Note 21).

Dividend income is recognized when the Group has the right to receive the dividend payment. Rent income is recognized in the financial statements when the Groups right to receive the monthly rent income is established.

Commission income is recognized when the intermediary goods’ invoice has been booked by the seller.

Bank borrowings

All bank borrowings are initially recognized at cost, being the fair value of the consideration received net of issue cost associated with the borrowing. After initial recognition, bank borrowings are subsequently measured at amortized cost using the effective yield method. Amortized cost is calculated by taking into account any issue cost and any discount or premium on settlement (Note 6).

Borrowing costs

Borrowing costs that are directly attributable to the acquisition, construction or production of a qualifying asset, one that takes a substantial period of time to get ready for its intended use or sale, are capitalised as part of the cost of that asset in the period in which the asset is prepared for its intended use or sale. Without this context, the borrowing costs are expensed as incurred.

Fair value of financial instruments

Fair (market) value is the amount for which a financial instrument could be exchanged in a current transaction between willing parties, other than in a forced sale or liquidation, and is best evidenced by a quoted market price, if one exists.

The fair values of the financial instruments are determined in accordance with the following methods and assumptions as follows:

Financial assets

Monetary assets for which fair value approximates carrying value are carried at cost in the financial statements and consists of cash and cash equivalents, their interest accruals, and other financial assets; and considered to approximate their respective carrying values due to their short-term nature and negligible credit losses. The carrying value of accounts receivable along with the related allowance for unearned income and uncollectibility are estimated to be their fair values.

**CONVENIENCE TRANSLATION INTO ENGLISH OF CONSOLIDATED
FINANCIAL STATEMENTS ORIGINALLY ISSUED IN TURKISH (NOTE 2.5)**

AKSA AKRİLİK KİMYA SANAYİİ A.Ş.

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2011**

(Amounts expressed in thousands of Turkish Lira (“TL”) unless otherwise indicated.)

NOTE 2 - BASIS OF PRESENTATION OF FINANCIAL STATEMENTS (Continued)

Financial liabilities

Monetary liabilities for which fair value approximates carrying value including accounts payable, short-term bank borrowings and other monetary liabilities are considered approximate their respective carrying values due to their short-term nature. The bank borrowings are stated at their amortized costs and transaction costs are included in the initial measurement of bank borrowings. The fair value of bank borrowings are considered to state their respective carrying values since the interest rate applied to bank borrowings are updated periodically by the lender to reflect active market price quotations. The carrying value of accounts payable along with the related allowance for unrealized cost is estimated to be their fair values.

Employee termination benefits

Under the Turkish Labour Law, the Company is required to pay termination benefits to each employee who has completed one year of service and whose employment is terminated without due cause, or who is called up for military service, dies or retires after completing 25 years of service (20 years for women) and achieves the retirement age (58 for women and 60 for men). As of 23 May 2002 since the related legislation was changed, some transition pre-retirement articles has been removed.

Under the Turkish Labour Law, the provision has been calculated by estimating the present value of the future probable obligation of the Company arising from the retirement of the employees (Note 14).

The Group has an employee benefit plan called “Seniority Incentive Bonus” (“Bonus”) which is paid to employees with a certain level of seniority. The Group accounts for this Bonus according to IAS 19, “Employee Benefits”. Seniority incentive bonus provision which is disclosed within the employee termination benefit represents the present value of the estimated total reserve of the probable future obligations.

Current and deferred income tax

Tax expense or income is the aggregate of current income tax and deferred taxes which are based on the gains and losses for the period.

Deferred income tax is determined, using the liability method and tax rates (and laws) that have been enacted by the balance sheet date. Deferred income tax is provided in full, on temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the consolidated financial statements.

Deferred income tax assets resulting from deductible temporary differences are recognized to the extent that it is probable that future taxable profit will be available against which the deductible temporary difference can be utilized. The carrying amount of deferred tax assets is reviewed at each balance sheet date and reduced to the extent that it is no longer probable that sufficient taxable profit will be available to allow all or part of the deferred tax asset to be utilized. Deferred taxes arising from income and expenses accounted under equity are recorded under equity, accordingly.

Deferred tax assets and liabilities are measured at the tax rates that are expected to apply to the period when the asset is realized or the liability is settled, based on tax rates that have been enacted or substantively enacted at the balance sheet date. The carrying amount of deferred income tax assets is reviewed by the Group at each balance sheet date and reduced to the extent that it is no longer probable that sufficient taxable profit will be available to allow all or part of the deferred income tax asset to be utilized (Note 23).

**CONVENIENCE TRANSLATION INTO ENGLISH OF CONSOLIDATED
FINANCIAL STATEMENTS ORIGINALLY ISSUED IN TURKISH (NOTE 2.5)**

AKSA AKRİLİK KİMYA SANAYİİ A.Ş.

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2011**

(Amounts expressed in thousands of Turkish Lira (“TL”) unless otherwise indicated.)

NOTE 2 - BASIS OF PRESENTATION OF FINANCIAL STATEMENTS (Continued)

Earnings per share

Earnings per share disclosed in the income statement are determined by dividing net income by the weighted average number of shares that have been outstanding during the related period concerned (Note 24).

In Turkey, companies can increase their share capital by making a pro-rata distribution of shares (“bonus shares”) to existing shareholders from retained earnings. For the purpose of earnings per share computations, the weighted average number of shares outstanding during the year has been adjusted in respect of bonus shares issued without a corresponding change in resources by giving them retroactive effect for the year in which they were issued and for each earlier period.

Events after the balance sheet date

The Group adjusts the amounts recognised in its financial statements to reflect the adjusting events after the balance sheet date. If non-adjusting events after the balance sheet date have material influence on the economic decisions of users of the financial statements, they are disclosed in the notes to the consolidated financial statements.

Provisions

Provisions are recognised when the Group has a present legal or constructive obligation as a result of past events, it is probable that an outflow of resources will be required to settle the obligation and a reliable estimate of the amount can be made. Provisions are reviewed at each balance sheet date and adjusted to reflect the current best estimate (Note 13).

Contingent assets and liabilities

Contingent liabilities are not recognized in the financial statements, but are disclosed unless the possibility of an outflow of resources embodying economic benefits is remote. A contingent asset is not recognized in the financial statements, but disclosed when an inflow of economic benefits is probable.

Offsetting

If the essence of the transaction and events requires offsetting, presentation of these transactions and events at their net values or following up of the assets at their amounts after the deduction of impairment, is not evaluated as a breach of the non-deductibility rule.

Foreign currency transactions

Foreign currency transactions are translated using the exchange rates prevailing at the dates of the transactions. Monetary assets and liabilities denominated in foreign currency are translated using the exchange rates at the balance sheet date. Foreign exchange gains and losses resulting from the translation of monetary assets and liabilities denominated in foreign currencies are recognised in the statements of income.

CONVENIENCE TRANSLATION INTO ENGLISH OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN TURKISH (NOTE 2.5)

AKSA AKRİLİK KİMYA SANAYİİ A.Ş.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2011

(Amounts expressed in thousands of Turkish Lira (“TL”) unless otherwise indicated.)

NOTE 2 - BASIS OF PRESENTATION OF FINANCIAL STATEMENTS (Continued)

Goodwill

The cost of a business combination is allocated by recognising the acquiree’s identifiable assets at the date of acquisition. Any excess of the acquirer’s interest in the net fair value of the acquiree’s identifiable assets, over the business combination cost is accounted for as goodwill.

The carrying value of goodwill is reviewed annually at the same time for impairment and the impairment provision, if any, is immediately recognised in the consolidated income statements. The recoverable amount of a cash generating unit is determined based on the value in use or fair value less cost to sell calculations. As a result of the impairment tests performed under above assumptions, no impairment was detected in the goodwill amount as of 31 December 2011. Since the sales cost-based fair value of the said cash generating unit is higher than the book value, the Group management did not make a recoverable value calculation according to the use value (Note 12).

Segment reporting

Operating segments are reported in a manner consistent with the reporting provided to the chief operating decision-maker. The chief operating decision-maker is responsible for allocating resources and assessing performance of the operating segments.

For an operating segment to be identified as a reportable segment, its reported revenue, including both sales to external customers and intersegment sales or transfers, is 10 per cent or more of the combined revenue, internal and external, of all operating segments; the absolute amount of its reported profit or loss is 10 per cent or more of the combined profit or loss or its assets are 10 per cent or more of the combined assets of all operating segments. Operating segments that do not meet any of the quantitative thresholds may be considered reportable, and separately disclosed, if the management believes that information about the segment would be useful to users of the financial statements.

For at the Group the reportable segments are industrial segments. Reportable segment, its reported revenue, including both sales to external customers and intersegment sales or transfers, is 10 per cent or more of the combined revenue, internal and external, of all operating segments; the absolute amount of its reported profit or loss is 10 per cent or more of the combined profit or loss or its assets are 10 per cent or more of the combined assets of all operating segments (Note 3).

The Group assesses the performance of the operating segments based on a measure of adjusted Earnings Before Interest, Tax, Depreciation and Amortisation, “EBITDA”.

The Group’s reportable business segments are “fibers”, “energy” and the remained operations are reported as “other”. Among the subsidiaries Aksa Egypt is included under “fibers”, Fitco and Ak-tops are reported under “other” segment (Note 3).

The supportive functions of industrial segments namely Financial Affairs, Human Resources and Management of Systems, Purchasing, Business Development, Research and Development, Head Office Expenses and other general administrative and operating expenses are classified under unallocated corporate expenses. Unallocated corporate expenses are followed at the Group level by management as the expenses are made to ensure the integrity of the Group by the management.

CONVENIENCE TRANSLATION INTO ENGLISH OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN TURKISH (NOTE 2.5)

AKSA AKRİLİK KİMYA SANAYİİ A.Ş.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2011

(Amounts expressed in thousands of Turkish Lira (“TL”) unless otherwise indicated.)

NOTE 2 - BASIS OF PRESENTATION OF FINANCIAL STATEMENTS (Continued)

Derivative financial instruments

The derivative instruments of the Group mainly consist of foreign exchange forward contracts and currency swap instruments. These derivative transactions, even though providing effective economic hedges under the Group risk management position, do not generally qualify for hedge accounting under the specific rules and are therefore treated as derivatives held for trading (IAS 39).

The Group shows its profits and losses relating to the hedging transaction under equities as “hedging fund”.

All derivatives are carried as assets when the fair value is positive and as liabilities when the fair value is negative (Note 16).

Related parties

Parties are considered related to the Group if;

- a) directly, or indirectly through one or more intermediaries, the party:
 - i) controls, is controlled by, or is under common control with, the Company (this includes parents, subsidiaries and fellow subsidiaries);
 - ii) has an interest in the Group that gives it significant influence over the Group; or
 - iii) has joint control over the Group;
 - b) the party is an associate of the Group;
 - c) the party is a joint venture in which the Group is a venture;
 - d) the party is member of the key management personnel of the Group or its parent;
 - e) the party is a close member of the family of any individual referred to in (a) or (d);
 - f) the party is an entity that is controlled, jointly controlled or significantly influenced by, or for which significant voting power in such entity resides with, directly or indirectly, any individual referred to in (d) or (e);
- or
- g) the party has a post-employment benefit plan for the benefit of employees of the Group, or of an entity that is a related party of the Group.

Related party transactions are transfer of resources or obligations between related parties, regardless of whether a price is charged.

A number of transactions are entered into with related parties in the normal course of business (Note 25).

CONVENIENCE TRANSLATION INTO ENGLISH OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN TURKISH (NOTE 2.5)

AKSA AKRİLİK KİMYA SANAYİİ A.Ş.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2011

(Amounts expressed in thousands of Turkish Lira (“TL”) unless otherwise indicated.)

NOTE 2 - BASIS OF PRESENTATION OF FINANCIAL STATEMENTS (Continued)

Reporting of cash flow

Cash flows during the period are classified and reported by operating, investing and financing activities in the cash flow statements.

Cash flows from operating activities represent the cash flows of the Group generated from retailing activities.

Cash flows related to investing activities represent the cash flows that are used in or provided from the investing activities of the Group (fixed investments and financial investments).

Cash flows arising from financing activities represent the cash proceeds from the financing activities of the Group and the repayments of these funds.

Cash and cash equivalents comprise cash on hand and bank deposits and short-term, highly liquid investments that are readily convertible to known amounts of cash with maturities equal or less than three months and which are subject to an insignificant risk of changes in value (Note 4).

Government grants

Grants from the government are recognised at their fair value where there is a reasonable assurance that the grant will be received and the group will comply with all attached conditions. Government grants relating to costs are recognised in the income statement by deducting from research and development expenses. Government grants relating to property, plant and equipment are included in non-current liabilities as deferred government grants and are credited to the income statement on a straight-line basis over the expected lives of the related assets.

2.4 Critical Accounting Judgements, Estimates and Assumptions

The preparation of financial statements necessitates the use of estimates and assumptions that affect asset and liability amounts reported as of the balance sheet date, explanations of contingent liabilities and assets; and income and expense amounts reported for the accounting period. Although these estimates and assumptions are based on all management information related to the events and transactions, actual results may differ from them.

The estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities for the next reporting period are outlined below:

a) Goodwill impairment tests

Goodwill represents the excess of the cost of an acquisition over the fair value of the Group’s share of the net identifiable assets of the acquired subsidiary at the date of acquisition.

CONVENIENCE TRANSLATION INTO ENGLISH OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN TURKISH (NOTE 2.5)

AKSA AKRİLİK KİMYA SANAYİİ A.Ş.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2011

(Amounts expressed in thousands of Turkish Lira (“TL”) unless otherwise indicated.)

NOTE 2 - BASIS OF PRESENTATION OF FINANCIAL STATEMENTS (Continued)

The Group tests annually goodwill for impairment and carries goodwill at cost less accumulated impairment loss. The recoverable amount of cash-generating unit has been determined based on value-in-use calculations. These value-in-use calculations include the discounted after tax cash flow projections, and these projections are based on USD financial budgets approved by management covering a five-year period. The USD fair value is converted into TL by using the related foreign exchange rate on the date of the balance sheet. Therefore, the value in use calculations is affected by the fluctuations in the foreign exchange market.

The discount rate used in the value in use calculations is 10,59% and the risk premium is 3%. The discount rates used are after tax and reflect specific risks relating to the company. As of 31 December 2011, the Group did not determine any impairment in the amount of the goodwill as a result of the impairment test performed by using the aforementioned assumptions.

If discount rate used in goodwill impairment calculation has been 2% higher/lower with all other variables held constant, there would not been any impairment define on goodwill amount.

b) Net realizable value

Inventories are valued at the lower of cost or net realizable value as discussed in Note:2.3. Net realizable value is the estimated selling price in the ordinary course of business, less estimated costs of completion and estimated costs necessary to make the sale (Note 9).

c) Tangible and intangible assets’ useful lives

Property, plant and equipment are stated at cost less accumulated depreciation and accumulated impairment loss as discussed in Note 2.3. They are initially recognised at acquisition cost and amortised on a straight-line basis over their estimated useful lives. Useful lives of property, plant and equipment, rely on best estimates of management, these estimates are reviewed balance sheet dates and if necessary adjustments are made necessary.

Useful lives change of plant, property and equipment

In 2011, Group has reviewed useful lives of some property, plant and equipments in fiber segment according to IAS 16 “ Property, plant and equipment” , as a result of the study, estimated useful lives of these tangible fixed assets have been changed effective from 1 January 2011. As a result of this change, current period amortisation expense decreased by TL 8.299 compared to amount calculated with prior useful life estimation as of 31 December 2011.

Useful lives changes as follows;

	New Useful lives	Previous Useful lives
Machinery and equipment	17-30 years	10 years
Land improvemens	30 years	15 years

d) Doubtful provision

In the event there is a situation which makes impossible for the Group to collect the amounts due payable, a provision for loss is created for the trade receivables. The amount of the provision is determined with the assessment of the payment performance of the customer and trade receivable aging. Provision for doubtful receivables is the accounting estimation that is based on the past payment performance and financial situations of the customers (Note 7).

CONVENIENCE TRANSLATION INTO ENGLISH OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN TURKISH (NOTE 2.5)

AKSA AKRİLİK KİMYA SANAYİİ A.Ş.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2011

(Amounts expressed in thousands of Turkish Lira (“TL”) unless otherwise indicated.)

NOTE 2 - BASIS OF PRESENTATION OF FINANCIAL STATEMENTS (Continued)

e) Provisions

As discussed in Note 2.3, provisions are recognized when the Group has a present legal or constructive obligation as a result of past events, when it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and when reliable estimate can be made of the amount of the obligation (Note 13).

2.5 Convenience Translation into English of Consolidated Financial Statements

As of 31 December 2011, the financial reporting standards described in Note 2.1 (defined as “CMB” Financial Reporting Standards) to the consolidated financial statements differ from IFRS issued by the International Accounting Standards Board with respect to the application of inflation accounting for the periods between 1 January and 31 December 2005. Accordingly, these consolidated financial statements are not intended to present the financial position and the results of operations in accordance with IFRS

USD amounts shown in these consolidated financial statements have been included solely for the convenience of the reader and are translated from TL, as a matter of arithmetic computation only, at the Central Bank of the Republic of Turkey official TL exchange rate. Thus, USD amounts do not form a part of the consolidated financial statements prepared in accordance with generally accepted accounting standards issued by the CMB as at 31 December 2011.

NOTE 3 - SEGMENT REPORTING

Segmental information of the Group is as follows:

	1 January- 31 December 2011			
	Fibers	Energy	Other	Total
Total segment revenue	1.634.482	46.829	37.627	1.718.938
Inter-segment revenue	-	(7.552)	(35.916)	(43.468)
External revenues	1.634.482	39.277	1.711	1.675.470
Adjusted EBITDA	227.720	13.159	(2.828)	238.051
Unallocated corporate expenses (*)				(45.233)
Amortization and depreciation (Note 19)	(36.834)	(5.707)	(4.053)	(46.594)
Other expenses, net (Note 20)				(4.052)
Financial expenses, net (Note 21-22)				(20.444)
Profit before tax				121.728

(*) As of 31 December 2011, unallocated corporate expenses consists of general administrative expenses amounting to TL 42.541, research and development expenses amounting to TL 2.692.

**CONVENIENCE TRANSLATION INTO ENGLISH OF CONSOLIDATED
FINANCIAL STATEMENTS ORIGINALLY ISSUED IN TURKISH (NOTE 2.5)**

AKSA AKRİLİK KİMYA SANAYİİ A.Ş.

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2011**

(Amounts expressed in thousands of Turkish Lira ("TL") unless otherwise indicated.)

NOTE 3 - SEGMENT REPORTING (Continued)

	1 January- 31 December 2011			
	Fibers	Energy	Other	Total
Capital expenditure	91.887	145.457	8.332	245.676
				31 December 2011
Total segment assets	1.100.686	330.687	34.458	1.465.831
Inter-segment adjustments and classification	-	(348)	(6.276)	(6.624)
Unallocated corporate assets				193.358
Total assets	1.100.686	330.339	28.182	1.652.565
Total segment liabilities	252.500	16.096	3.541	272.137
Inter-segment adjustments and classification	(6.276)	-	(348)	(6.624)
Unallocated corporate liabilities				536.105
Total liabilities	246.224	16.096	3.193	801.618
				1 January- 31 December 2010
	Fibers	Energy	Other	Total
Total segment revenue	1.222.605	51.986	73.345	1.347.936
Inter-segment revenue	-	(7.367)	(36.257)	(43.624)
External revenues	1.222.605	44.619	37.088	1.304.312
Adjusted EBITDA	163.376	13.894	782	178.052
Unallocated corporate expenses (*)				(42.450)
Amortization and depreciation (Note 19)	(46.849)	(3.800)	(3.994)	(54.643)
Other income, net (Note 20)				(67)
Financial expenses, net (Note 21-22)				(5.122)
Profit before tax				75.770

(*) As of 31 December 2010, unallocated corporate expenses consists of general administrative expense amounting to TL 39.165, research and development expenses amounting to TL 3.285.

**CONVENIENCE TRANSLATION INTO ENGLISH OF CONSOLIDATED
FINANCIAL STATEMENTS ORIGINALLY ISSUED IN TURKISH (NOTE 2.5)**

AKSA AKRİLİK KİMYA SANAYİİ A.Ş.

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2011**

(Amounts expressed in thousands of Turkish Lira (“TL”) unless otherwise indicated.)

NOTE 3 - SEGMENT REPORTING (Continued)

	1 January - 31 December 2010			
	Fibers	Energy	Other	Total
Capital expenditure	32.673	126.652	6.784	166.109
				31 December 2010
Total segment assets	920.216	203.964	169.125	1.293.305
Inter-segment adjustments and classifications	(127.875)	(838)	(7.140)	(135.853)
Unallocated corporate assets				201.450
Total assets	792.341	203.126	161.985	1.358.902
Total segment liabilities	187.667	37.057	134.476	359.200
Inter-segment adjustments and classifications	(7.140)	-	(128.713)	(135.853)
Unallocated corporate liabilities				359.790
Total liabilities	180.527	37.057	5.763	583.137

Segment Assets

Reconciliation between the reportable segment assets and total assets as follows:

	31 December 2011	31 December 2010
Reportable segment assets	1.459.207	1.157.453
Cash and cash equivalents	85.106	64.499
Other receivables	185	36.930
Other assets	86.638	77.947
Financial investments	1.385	8.008
Tangible and intangible assets	14.055	8.076
Goodwill	5.989	5.989
Total assets	1.652.565	1.358.902

CONVENIENCE TRANSLATION INTO ENGLISH OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN TURKISH (NOTE 2.5)

AKSA AKRİLİK KİMYA SANAYİİ A.Ş.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2011

(Amounts expressed in thousands of Turkish Lira ("TL") unless otherwise indicated.)

NOTE 3 - SEGMENT REPORTING (Continued)

Segment Liabilities

Reconciliation between the reportable segment liabilities and total liabilities as follows:

	31 December 2011	31 December 2010
Reportable segment liabilities	265.513	223.347
Financial liabilities (*)	493.231	310.565
Derivative financial instruments (**)	4.175	5.000
Other liabilities	2.072	3.808
Provisions	2.382	1.396
Taxes on income	369	3.839
Other liabilities	14.207	19.334
Provision for employment benefits	2.487	2.385
Deferred income tax liabilities	17.182	13.463
Total liabilities	801.618	583.137

(*) As of 31 December 2011, TL 114.614 (31 December 2010: TL 124.450) of the borrowings issued for energy unit investment and TL 265.247 (31 December 2010: TL 61.947) is secured for fiber investments.

(**) As of 31 December 2010, the swap agreement liability, amounting to TL 3.077 (31 December 2010: TL 3.793) of the derivative financial instruments is related to borrowings for fiber investment and amounting to TL 1.098 (31 December 2010: TL 1.204) of the derivative financial instruments is related to borrowings for energy investment.

NOTE 4 - CASH AND CASH EQUIVALENTS

Details of cash and cash equivalents of the Group as follows:

	31 December 2011	31 December 2010
Cash	104	169
Bank		
Demand deposit (TL)	10.042	4.776
foreign currency demand deposit	12.770	7.393
time deposits (TL)	13.732	17.095
foreign currency time deposit	47.122	34.616
Other	1.336	450
Total	85.106	64.499

Maturity of time deposit are less than three months and weighted average effective interest rates on TL denominated time deposits at 31 December 2011 is 11,01% (31 December 2010: 8,25%) and for USD 4,44% (31 December 2010: 2,91%), respectively. Weighted average effective interest rates of Euro denominated time deposits are 4,41% (31 December 2010: 1,70%).

CONVENIENCE TRANSLATION INTO ENGLISH OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN TURKISH (NOTE 2.5)

AKSA AKRİLİK KİMYA SANAYİİ A.Ş.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2011

(Amounts expressed in thousands of Turkish Lira (“TL”) unless otherwise indicated.)

NOTE 4 - CASH AND CASH EQUIVALENTS (Continued)

The analysis of cash and cash equivalents in terms of consolidated statements of cash flows is as follows:

	31 December 2011	31 December 2010	31 December 2009
Cash and cash equivalents	85.106	64.499	102.212
Less: Restricted cash with maturity of three months or less	(1.336)	(450)	(442)
Interest accrual	(79)	(32)	(98)
Cash and cash equivalents	83.691	64.017	101.672

NOTE 5 - FINANCIAL INVESTMENTS

Details of financial assets of the Group is as follows:

	31 December 2011	31 December 2010
Unquoted financial assets:		
Ak-Pa (*)	1.327	-
Akgirişim	58	58
Fitco (**)	-	7.863
Aksa Egypt (**)	-	87
Total	1.385	8.008

(*) The Company ceased to have the power to govern the operational and financial policies of Ak-Pa Tekstil İhracat Pazarlama A.Ş. Ak-pa is excluded from the scope of consolidation as of 1 January 2011 and as of that date, the fair value of AK-PA which is corresponding to participation rate of the Company is included in the consolidated financial statements.

(**) As of 1 January 2011, Aksa Egypt and Fitco, subsidiaries of the Group, have been included to full consolidation scope due to per their increasing importance on the grounds of materiality.

Akgirişim, the subsidiary is not included in the scope of consolidation on the grounds of materiality due to the insignificance of their impact on the consolidated net worth assets, financial position and results of the Group. They are accounted for under short term financial assets at their acquisition cost as they do not have a quoted market price in active markets.

**CONVENIENCE TRANSLATION INTO ENGLISH OF CONSOLIDATED
FINANCIAL STATEMENTS ORIGINALLY ISSUED IN TURKISH (NOTE 2.5)**

AKSA AKRİLİK KİMYA SANAYİİ A.Ş.

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2011**

(Amounts expressed in thousands of Turkish Lira ("TL") unless otherwise indicated.)

NOTE 6 - FINANCIAL LIABILITIES

Group's financial liabilities are as follows:

	31 December 2011	31 December 2010
Short term bank borrowings	114.227	113.384
Short term factoring liabilities	-	10.035
Current portion of long term bank borrowings	58.759	47.839
Short term financial liabilities	172.986	171.258
Long term bank borrowings	320.245	139.307
Total financial liabilities	493.231	310.565

Bank Loans

	31 December 2011		31 December 2010	
	Yearly weighted average interest rate %	TL	Yearly weighted average interest rate %	TL
Short term bank borrowings:				
USD borrowings	1,78	114.185	2,12	109.865
TL borrowings	-	42	7,25	3.519
		114.227		113.384
Factoring Liabilities		-		10.035
Current portion of long term bank borrowings:				
USD borrowings	3,54	58.759	3,48	47.839
Total short term bank borrowings		172.986		171.258
Long term bank borrowings:				
USD borrowings	3,54	320.245	3,48	139.307

**CONVENIENCE TRANSLATION INTO ENGLISH OF CONSOLIDATED
FINANCIAL STATEMENTS ORIGINALLY ISSUED IN TURKISH (NOTE 2.5)**

AKSA AKRİLİK KİMYA SANAYİİ A.Ş.

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2011**

(Amounts expressed in thousands of Turkish Lira (“TL”) unless otherwise indicated.)

NOTE 6 - FINANCIAL LIABILITIES (Continued)

The long term bank borrowings’ fair values and book values as follows:

	31 December 2011		31 December 2010	
	Fair Value	Book Value	Fair Value	Book Value
USD borrowings (*)	354.047	320.245	152.923	139.307

(*) Calculated by taking into account swap interest rates.

The redemption schedule of borrowings is as follows

	31 December 2011	31 December 2010
Less than 3 months	2.670	24.958
Between 3-12 months	170.316	146.300
Between 1-2 years	56.618	46.491
Between 2-3 years	72.291	46.436
Between 3-4 years	26.957	46.380
The payment with in 4 year and over	164.379	-
	493.231	310.565

As of 31 December 2011, according to the credit agreements, the Group has unused credit limit amounting to TL 1.127.883 (31 December 2010: TL 1.001.137).

NOTE 7 - TRADE RECEIVABLES AND PAYABLES

Details of trade receivables of the Group as follows:

Short-term Trade Receivables:

	31 December 2011	31 December 2010
Trade receivables	309.025	337.985
Less: Provision for doubtful receivables	(40.236)	(28.789)
Provision for sales discount premium	(94)	-
Unearned finance income on term based sales	(2.231)	(2.053)
Total short-term trade receivables, net	266.464	307.143

Trade receivables as of 31 December 2011 and 31 December 2010 have an average maturity of 3 months and they are discounted with an average annual interest rate of 8%.

The past experience of the Group in collecting receivables has been taken into consideration when determining the provision amount for doubtful receivables. Therefore, the Group believes that, there are no collection risks for trade receivables other than the provision taken for possible collection risks.

**CONVENIENCE TRANSLATION INTO ENGLISH OF CONSOLIDATED
FINANCIAL STATEMENTS ORIGINALLY ISSUED IN TURKISH (NOTE 2.5)**

AKSA AKRİLİK KİMYA SANAYİİ A.Ş.

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2011**

(Amounts expressed in thousands of Turkish Lira (“TL”) unless otherwise indicated.)

NOTE 7 - TRADE RECEIVABLES AND PAYABLES (Continued)

Movements of provision for doubtful receivables for 31 December 2011 and 2010 are as follows:

	2011	2010
1 January	28.789	26.276
Collections and reversal of provisions	(185)	(464)
Current period charge	11.632	2.977
31 December	40.236	28.789

Long term trade receivables:

	31 December 2011	31 December 2010
Notes receivables and cheques	1.090	9.729
Less: Unearned finance income on term based sales (-)	(16)	(176)
Total long term trade receivables, net	1.074	9.553

The explanation for the nature and level of the risk in trade receivables is shown in Note 26 Credit Risk section.

Short term trade payables:

	31 December 2011	31 December 2010
Suppliers	228.040	176.631
Less: Unincurred finance costs on purchases (-)	(1.905)	(1.337)
Total	226.135	175.294

Trade payables as of 31 December 2011 and 2010 have an average maturity of 3 months and they are discounted with an average annual interest rate of 4% (2010: 5%).

**CONVENIENCE TRANSLATION INTO ENGLISH OF CONSOLIDATED
FINANCIAL STATEMENTS ORIGINALLY ISSUED IN TURKISH (NOTE 2.5)**

AKSA AKRİLİK KİMYA SANAYİİ A.Ş.

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2011**

(Amounts expressed in thousands of Turkish Lira ("TL") unless otherwise indicated.)

NOTE 8 - OTHER RECEIVABLES AND PAYABLES

Details of other receivables and payables of the Group as follows:

Short term other receivables:	31 December 2011	31 December 2010
Deposits and guarantees given	223	155
Due from related parties (Note 25)	-	36.763
Total	223	36.918

Short term other payables:	31 December 2011	31 December 2010
Accrued tax liability	1.931	3.655
Other	141	153
Total	2.072	3.808

NOTE 9 - INVENTORIES

	31 December 2011	31 December 2010
Raw materials	124.882	91.339
Semi-finished goods	20.272	7.890
Finished goods	35.005	50.787
Merchandise stocks	-	1.644
Other stocks and spare parts	12.459	11.788
Less: Provision for impairment in inventories	(1.243)	(3.952)
Total	191.375	159.496

The inventory impairment provision is mainly related with the finished goods.

The stocks of raw materials which are recognized as expense at current period, shown in cost of sales and their amounts are presented at Note 19.

Group has included the movements in the provision for impairment to cost of goods sold between 31 December 2011 and 2010. The decrease in provision for the impairment amount is partially due to the sale of inventory and increase in sales prices.

CONVENIENCE TRANSLATION INTO ENGLISH OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN TURKISH (NOTE 2.5)

AKSA AKRİLİK KİMYA SANAYİİ A.Ş.

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2011**

(Amounts expressed in thousands of Turkish Lira (“TL”) unless otherwise indicated.)

NOTE 10 - TANGIBLE ASSETS

	1 January 2011	Additions	Disposals	Transfers (1) (2)	Changes in the scope of consolidation (3)	Currency translation differences	31 December 2011
Cost							
Land	59.457	2.341	(54)	713	1.154	-	63.611
Land improvements	43.925	-	-	35.815	-	-	79.740
Buildings	109.640	800	(297)	45.368	(1.418)	-	154.093
Machinery and equipment	748.983	3.365	-	186.993	4.459	-	943.800
Motor vehicles	1.358	84	(234)	-	241	-	1.449
Furniture and fixtures	23.255	1.101	-	2.097	(26)	-	26.427
Construction in progress	221.633	239.379	-	(288.170)	-	-	172.842
	1.208.251	247.070	(585)	(17.184)	4.410	-	1.441.962
Accumulated depreciation							
Land improvements	27.676	2.667	-	-	-	-	30.343
Buildings	33.357	2.445	(81)	-	(786)	14	34.949
Machinery and equipment	471.004	43.903	-	-	4.265	12	519.184
Motor vehicles	912	169	(204)	-	133	5	1.015
Furniture and fixtures	16.360	1.205	-	-	(9)	-	17.556
	549.309	50.389	(285)	-	3.603	31	603.047
Net book value	658.942						838.915

(1) The transfer of TL 232.622 is related with capitization of Company’s energy plant investment.

(2) The transfer of TL 17.184 is related with intangible fixed assets (Note 11).

(3) Related with exclusion of Ak-Pa from the scope of consolidation, inclusion of Fitco and Aksa Egypt in the scope of full consolidation as of 1 January 2011.

Additions to construction in progress are mainly comprised of expenditures related with the coal plant and carbon fiber investments.

For the year ended 31 December 2011, borrowing costs amounting to TL 24,073 related with power plant investment, carbon fiber investment and efficiency projects have been capitalised on property, plant and equipment.

TL 44,114 of current year depreciation and amortization expense is charged to “cost of goods sold”, TL 1 is charged to “research and development expenses”, TL 556 is included in “general administrative expenses”, TL 16 is included in “selling and marketing costs”, TL 2.189 which is related with projects in progress is charged to “construction in progress”, TL 3.513 is included in closing “inventory”. As of 31 December 2011 there is no mortgage on property, plant and equipment.

AKSA AKRİLİK KİMYA SANAYİİ A.Ş.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2011

(Amounts expressed in thousands of Turkish Lira (“TL”) unless otherwise indicated.)

NOTE 10 - TANGIBLE ASSETS (Continued)

	1 January 2010	Additions	Disposals	Transfers (1) (2)	Changes in the scope of consolidation (3)	Currency translation differences	31 December 2010
Cost							
Land	59.187	270	-	-	-	-	59.457
Land improvements	35.475	-	(101)	8.551	-	-	43.925
Buildings	109.595	59	(495)	481	-	-	109.640
Machinery and equipment	730.703	524	(83)	17.839	-	-	748.983
Motor vehicles	1.257	101	-	-	-	-	1.358
Furniture and fixtures	20.742	2.083	(4)	434	-	-	23.255
Construction in progress	83.935	165.009	-	(27.311)	-	-	221.633
	1.040.894	168.046	(683)	(6)	-	-	1.208.251
Accumulated depreciation							
Land improvements	25.920	1.759	(3)	-	-	-	27.676
Buildings	31.175	2.248	(66)	-	-	-	33.357
Machinery and equipment	419.311	51.722	(29)	-	-	-	471.004
Motor vehicles	803	109	-	-	-	-	912
Furniture and fixtures	15.363	998	(1)	-	-	-	16.360
	492.572	56.836	(99)	-	-	-	549.309
Net book value	548.322						658.942

Construction in progress additions mainly comprise of expenditures with the coal plant and carbon fiber investments.

As of ended year 31 December 2010 borrowing costs amounting to TL 6.555 related with coal plant investment has been capitalised on property, plant and equipment TL 51.810 of the depreciation and amortization expense is charged to “cost of goods sold”, TL 254 is charged to “research and development expenses”, TL 894 expense is included in “general administrative expenses”, TL 75 is included in “selling and marketing costs, TL 2.032 is related with projects in progress, development costs amortisation is charged to “construction in progress”, TL 1.771 is included in closing “inventory”.

As of 31 December 2010 there is no mortgage on property, plant and equipment.

AKSA AKRİLİK KİMYA SANAYİİ A.Ş.

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2011**

(Amounts expressed in thousands of Turkish Lira (“TL”) unless otherwise indicated.)

NOTE 11 - INTANGIBLE ASSETS

	1 January 2011	Additions	Transfer (1)	Changes in the Scope of consolidation (2)	Currency translation differences	31 December 2011
Cost						
Rights	1.648	726	-	542	77	2.993
Development cost	7.117	-	17.184	-	-	24.301
Other intangible assets	1.577	69	-	-	-	1.646
	10.342	795	17.184	542	77	28.940
Accumulated depreciation						
Rights	1.480	146	-	445	15	2.086
Development cost	2.316	1.672	-	-	-	3.988
Other intangible assets	1.371	89	-	-	-	1.460
	5.167	1.907	-	445	15	7.534
Net book value	5.175					21.406
	1 January 2010	Additions	Transfer (1)	Changes in the Scope of consolidation (2)	Currency translation differences	31 December 2010
Cost						
Rights	1.648	-	-	-	-	1.648
Development cost	7.117	-	-	-	-	7.117
Other intangible assets	1.476	95	6	-	-	1.577
	10.241	95	6	-	-	10.342
Accumulated depreciation						
Rights	1.463	17	-	-	-	1.480
Development cost	830	1.486	-	-	-	2.316
Other intangible assets	1.264	107	-	-	-	1.371
	3.557	1.610	-	-	-	5.167
Net book value	6.684					5.175

(1) Consists of the capitalized cost of development projects regarding to R&D Center.

(2) Related with exclusion of Ak-pa from the scope of consolidation, inclusion of Fitco and Aksa Egypt in the scope of full consolidation as of 1 January 2011.

AKSA AKRİLİK KİMYA SANAYİİ A.Ş.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2011

(Amounts expressed in thousands of Turkish Lira (“TL”) unless otherwise indicated.)

NOTE 11 - INTANGIBLE ASSETS (Continued)

TL 153 (2010: TL 108) of the current amortization expense is charged to “cost of goods sold”, TL 1.626 (2010: 1.486) is charged to “research and development expenses”, TL 128 (2010: TL 16) is included in “general administrative expenses.

NOTE 12 - GOODWILL

The goodwill balance with the carrying amount of TL5.989 (2010: TL5.989) as at 31 December 2011 resulted from the acquisition of 50% of shares Ak-Tops Tekstil Sanayi A.Ş. during 2007.

In Note 2.4 details of assessment for the impairment of Goodwill is defined. There is no change in the book value of the goodwill, which is TL5.989 for the period ended as of 31 December 2011 (31 December 2010: TL5.989).

NOTE 13 - PROVISIONS, CONTINGENT ASSETS AND LIABILITIES

Provisions:

	31 December 2011	31 December 2010
Provision for unused vacation (Note 14)	1.061	917
Provision for lawsuits	538	842
Provision for other payables and expenses	1.677	478
Total	3.276	2.237

Contingent assets and liabilities are as follows:

a) The details of collaterals, pledges and mortgages (“CPM”) of the Group are as follows:

	31 December 2011	31 December 2010
Letter of credit	249.213	180.490
Collaterals given	149.914	118.114
Total	399.127	298.604

b) CPM received for short term trade receivables are as follows:

	31 December 2011	31 December 2010
Credit insurance	139.522	-
Guarantee notes and cheques received	95.007	48.282
Limits of Eximbank	78.444	54.419
Pledges received	47.730	36.310
Confirmed/unconfirmed letter of credits	42.190	21.981
Limits of Direct Debit System (“DDS”)	29.464	17.749
Guarantee letters received	7.913	7.249
Total	440.270	185.990

AKSA AKRİLİK KİMYA SANAYİİ A.Ş.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2011

(Amounts expressed in thousands of Turkish Lira (“TL”) unless otherwise indicated.)

NOTE 13 - PROVISIONS, CONTINGENT ASSETS AND LIABILITIES (Continued)

c) Collaterals, Pledges, Mortgages(“CPM”):

	31 December 2011	31 December 2010
A. CPM given on behalf of the Company’s legal personality	397.151	298.604
-Turkish Lira	112.655	99.557
- USD	275.643	199.047
-Euro	3.519	-
-Other	5.334	-
B. CPM given on behalf of fully consolidated subsidiaries	-	-
C. CPM given for continuation of its economic activities on behalf of third parties	1.976	-
- USD	1.976	-
D. Total amount of other CPM given	-	-
i) Total amount of CPM given on behalf of the majority shareholder	-	-
ii) Total amount of CPM given to on behalf of other group companies which are not in scope of B and C	-	-
iii) Total amount of CPM given on behalf of third parties which are not in scope of C.	-	-
Total	399.127	298.604

NOTE 14 - EMPLOYEE BENEFITS

Short Term Employee Benefits	31 December 2011	31 December 2010
Provision for unused vacation (Note 13)	1.061	917
Long Term Employee Benefits		
Provision for employee termination benefits and employee termination incentive	14.220	13.168

Provision for employee termination benefits

Employee termination benefit provision is recorded according to the following descriptions.

Under the Turkish Labour Law, the Company is required to pay termination benefits to each employee who has completed one year of service and who reaches the retirement age (58 for women and 60 for men), whose employment is terminated without due cause, is called up for military service or passed away.

The liability is not funded as there is no funding requirement.

AKSA AKRİLİK KİMYA SANAYİİ A.Ş.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2011

(Amounts expressed in thousands of Turkish Lira (“TL”) unless otherwise indicated.)

NOTE 14 - EMPLOYEE BENEFITS (Continued)

The provision has been calculated by estimating the present value of the future probable obligation of the Company arising from the retirement of employees.

IAS 19 ‘Employee Benefits’ require actuarial valuation methods to be developed to estimate the enterprise’s obligation under defined benefit plans. Accordingly the following actuarial assumptions have been used in the calculation of the total liability:

	31 December 2011	31 December 2010
Discount rate (%)	2,91	4,66
Probability of retirement (%)	98,94	98,92

The principal assumption is that the maximum liability for each year of service will increase in line with inflation. Thus, the discount rate applied represents the expected real rate after adjusting for the anticipated effects of future inflation. . As the maximum liability is revised once every six months, the maximum amount of TL 2.805,04 effective from 1 January 2012 (1 January 2010: TL 2.623,23) has been taken into consideration in calculating the reserve for employment termination benefit of the Group.

Movements in the provision for employment termination benefits are as follows:

	2011	2010
Balances as of 1 January	13.168	11.520
Service cost	2.294	1.748
Interest cost	614	682
Changes in the scope of consolidation (Note 2.1.3)	(371)	-
Paid compensation	(2.170)	(1.568)
Actuarial losses	685	786
Balances as of 31 December	14.220	13.168

NOTE 15 - OTHER ASSETS AND LIABILITIES

Other current assets:

	31 December 2011	31 December 2010
VAT receivables	61.307	40.151
VAT to be transferred	17.168	26.588
Prepaid taxes and funds	5.522	-
Purchase advances given	2.024	8.863
Prepaid expenses	1.855	1.293
Job advances	1.598	1.309
Personnel advances	700	1.719
Total	90.174	79.923

AKSA AKRİLİK KİMYA SANAYİİ A.Ş.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2011

(Amounts expressed in thousands of Turkish Lira ("TL") unless otherwise indicated.)

NOTE 15 - OTHER ASSETS AND LIABILITIES (Continued)

Other non current assets:

	31 December 2011	31 December 2010
Advances given for purchase of property, plant and equipment	15.527	6.797
Other	95	110
Total	15.622	6.907

Other current liabilities:

	31 December 2011	31 December 2010
Deferred income (*)	978	978
Advances received	21	4.764
Other	509	123
	1.508	5.865

Other non current liabilities:

	31 December 2011	31 December 2010
Deferred income (*)	12.771	13.469
Other	51	-
Total	12.822	13.469

(*) Government grants are received as a reimbursement of the investments conducted in the context of Research and Development projects. Such grants are accounted for under current and non-current liabilities as deferred revenue and they are recognized in the consolidated income statement on a systematic basis over the estimated useful life of the related assets.

Incentives, grants and benefits which have been obtained from TÜBİTAK and Undersecretaries of the Prime Ministry for Foreign Trade regarding R&D projects and which have been received in cash in 2008 and 2009, are recognized in the consolidated statement of income on a systematic basis over 16 years, which has been determined as the estimated useful life of related assets.

NOTE 16 - DERIVATIVE FINANCIAL INSTRUMENTS

	31 December 2011		31 December 2010	
	Asset	Liability	Asset	Liability
Held for hedging	-	4.175	-	5.000

Derivative instruments held for hedging:

	31 December 2011		31 December 2010	
	Contract Amount	Fair value Liability	Contract amount	Fair value Liability
Interest rate swap transactions	90.747	4.175	99.031	5.000

AKSA AKRİLİK KİMYA SANAYİİ A.Ş.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2011

(Amounts expressed in thousands of Turkish Lira (“TL”) unless otherwise indicated.)

NOTE 16 - DERIVATIVE FINANCIAL INSTRUMENTS (Continued)

Derivative financial instruments are initially recognised in the consolidated balance sheet at cost and subsequently are re-measured at their fair value. The derivative instruments of the Group mainly consist of foreign exchange forward contracts and interest rate swap instruments. On the date a derivative contract is entered into, the Group designates certain derivatives as either a hedge of the fair value of a recognised asset or liability (“fair value hedge”), or a hedge of a forecasted transaction or a firm commitment (“cash flow hedge”).

These derivative transactions provide effective economic hedges under the Group risk management position and qualify for hedge accounting under the specific rules and are therefore treated as derivatives held for hedging. Changes in the fair value of derivatives that are designated as being and qualify as cash flow hedges and are highly effective, are recognised in equity as “hedging reserve”.

When a hedging instrument expires or is sold, or when a hedge no longer meets the criteria for hedge accounting, or when a committed or forecasted transaction is no longer expected to occur, the cumulative gain or loss that was reported in equity is immediately transferred to the consolidated income statement.

When a hedging instrument expires or is sold, or when a hedge no longer meets the criteria for hedge accounting, or when a committed or forecasted transaction is no longer expected to occur, the cumulative gain or loss that was reported in equity is immediately transferred to the consolidated income statement.

As of 31 December 2011, the fixed interest rates vary from %2,5 to %4,2 (31 December 2010: %2,5 - %4,2). The main floating rates are EURIBOR and LIBOR. Gains and losses recognised in the hedging reserve in equity on interest rate swap contracts as of 31 December 2011 will be continuously released to the income statement within finance cost until the repayment of the bank borrowings (Note 5).

NOTE 17 - EQUITY

Aksa has adopted the registered share capital system applicable to companies registered on the CMB and set a limit on its registered share capital representing type of registered shares with a nominal value of TL 1. Historical, authorized and issued capital of Aksa as of 31 December 2011 and 2010 is presented below:

	31 December 2011	31 December 2010
Limit on registered share capital (historical)	425.000	425.000
Issued share capital in nominal value	185.000	185.000

AKSA AKRİLİK KİMYA SANAYİİ A.Ş.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2011

(Amounts expressed in thousands of Turkish Lira ("TL") unless otherwise indicated.)

NOTE 17 - EQUITY (Continued)

The Company's shareholders and their respective shareholding structure as follows:

	Share %	31 December 2011	Share %	31 December 2010
Akkök Sanayi Yatırım ve Geliştirme A.Ş.	39,59	73.237	39,59	73.237
Emniyet Ticaret ve Sanayi A.Ş.	18,72	34.638	18,72	34.638
Other	41,69	77.125	41,69	77.125
	100,00	185.000	100,00	185.000
Adjustment to share capital		195.175		195.175
Total paid-in share capital		380.175		380.175

The approved and paid-in share capital of the Company consists of 18.500.000.000 (31 December 2010: 18.500.000.000) shares issued on bearer with a nominal value of Kr 1 (31 December 2010: Kr 1) each.

Adjustment to share capital represents the difference between the amounts of the restatement effect of cash and cash equivalents contributions to share capital and the amounts before the restatements.

The legal reserves consist of first and second reserves, appropriated in accordance with the Turkish Commercial Code ("TCC"), The TCC stipulates that the first legal reserve is appropriated out of statutory profits at the rate of 5% per annum, until the total reserve reaches 20% of the Company's paid-in capital. The second legal reserve is appropriated at the rate of 10% per annum of all cash distributions in excess of 5% of the paid-in capital. Under the TCC, the legal reserves can be used only to offset losses and are not available for any other usage unless they exceed 50% of paid-in capital.

In accordance with CMB Financial Reporting Standards, the Company classified the above mentioned amounts under "Restricted reserves", the amount of restricted reserves is TL52.542 as of 31 December 2011 (31 December 2010: TL 48.523). This amount fully consists of legal reserves.

In accordance with the CMB regulations effective until 1 January 2008, the inflation adjustment differences arising at the initial application of inflation accounting which are recorded under "accumulated losses" could be netted off from the profit to be distributed based on CMB profit distribution regulations.

In addition, the aforementioned amount recorded under "accumulated losses" could be netted off with net income for the period, if any, undistributed prior period profits, and inflation adjustment differences of extraordinary reserves, legal reserves and capital, respectively.

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2011**

(Amounts expressed in thousands of Turkish Lira (“TL”) unless otherwise indicated.)

NOTE 17 - EQUITY (Continued)

In accordance with the CMB regulations effective until 1 January 2008, “Capital, Share Premiums, Legal Reserves, Special Reserves and Extraordinary Reserves” were recorded at their statutory carrying amounts and the inflation adjustment differences related to such accounts were recorded under “inflation adjustment differences” at the initial application of inflation accounting. “Equity inflation adjustment differences” could have been utilised in issuing bonus shares and offsetting accumulated losses, carrying amount of extraordinary reserves could have been utilised in issuing bonus shares, cash dividend distribution and offsetting accumulated losses.

In accordance with the Communiqué No:XI-29 and related announcements of CMB, effective from 1 January 2008, “Share Capital”, “Restricted Reserves” and “Share Premiums” shall be carried at their statutory amount. The valuation differences shall be classified as follows:

- The difference arising from the “Paid-in Capital” and not been transferred to capital yet, shall be classified under the “Inflation Adjustment to Share Capital”;
- The difference due to the inflation adjustment of “Restricted Reserves” and “Share Premium” and the amount has not been utilised in dividend distribution or capital increase yet, shall be classified under “Retained Earnings”,

Other equity items shall be carried at the amounts calculated based on CMB Financial Reporting Standards.

Adjustment to share capital has no use other than being transferred to paid-in share capital.

Dividend Distribution

Based on CMB Decree No. 02/51, dated 27 January 2010, there is no mandatory minimum profit distribution requirement for the quoted entities at the stock exchange for profits arising from operations in 2009. Regarding the dividend distribution for the current and following years, the entities are to distribute their profits for the current and following years under the scope of CMB Communiqué No. IV-27, their articles of association and their previously publicly declared profit distribution policies. In regards to the profit distribution, in accordance with the decision of the General Assembly, the distribution can be made as cash or as bonus shares or as a combination of a certain percentage of cash and bonus shares. It is also permitted to retain this amount in the Company reserves if the first dividend amount is below 5% of the paid in/issued capital; however if the Company has increased its paid-in capital without dividend distribution in the previous year when the outstanding shares have been identified as “old” and “new”, it is mandatory for companies that will make profit distribution from the net distributable profit of the previous year to make this first dividend distribution in cash.

There is no other mandatory minimum profit distribution decision taken according to CMB.

AKSA AKRİLİK KİMYA SANAYİİ A.Ş.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2011

(Amounts expressed in thousands of Turkish Lira ("TL") unless otherwise indicated.)

NOTE 18 - REVENUE AND COST OF SALES

Sales and cost of goods sold for the year ended at 31 December 2011 and 2010 as follows:

	31 December 2011	31 December 2010
Domestic sales	1.105.026	828.791
Export sales	625.533	492.259
Commission income from foreign trade	-	665
Less: Sales returns	(6.839)	(3.965)
Other discounts	(48.250)	(13.438)
Net sales income	1.675.470	1.304.312
Cost of sales (-)	(1.442.272)	(1.142.683)
Gross profit	233.198	161.629

NOTE 19 - EXPENSES BY NATURE

Cost of sales, marketing, selling and distribution expenses and general administrative expenses by nature for the year ended as of 31 December 2011 and 2010 are as follows;

	31 December 2011	31 December 2010
Raw materials and goods	1.311.887	1.022.522
Personnel expenses	67.152	61.240
Depreciation and amortisation	46.594	54.643
Repair, maintenance and cleaning expenses	17.811	15.117
Commission expense	14.598	11.426
Export expenses	9.805	9.500
Consultancy expenses	9.557	8.282
Information technologies expense	6.166	4.409
Miscellaneous tax expenses	4.759	2.200
Travel expenses	3.686	3.646
Other	37.231	30.368
Total	1.529.246	1.223.353

NOTE 20 - OTHER OPERATING INCOME / EXPENSE

As of 31 December 2011 net other income/ expense amounting to TL (4.052) (2010: TL 67). Other income and expenses mainly comprise of TL 2.869 insurance compensation income (2010: TL 241), TL 3.059 (2010: 203 TL) scrap sales income, TL 1.513 R&D incentive income (2010: TL 1.344) and TL 11.632 of provision for doubtful trade receivable (2010: TL2.977) expenses.

AKSA AKRİLİK KİMYA SANAYİİ A.Ş.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2011

(Amounts expressed in thousands of Turkish Lira ("TL") unless otherwise indicated.)

NOTE 21 - FINANCIAL INCOME

Financial income for the year ended at 31 December 2011 and 2010 are as follows:

	31 December 2011	31 December 2010
Foreign exchange gains	132.853	96.660
Interest income from term based sales	15.590	17.712
Interest income	5.592	6.433
Total	154.035	120.805

NOTE 22 - FINANCIAL EXPENSES

Financial expense for the year ended at 31 December 2011 and 2010 are as follows:

	31 December 2011	31 December 2010
Foreign exchange expense	156.581	107.167
Due date charges on term purchases	11.028	13.143
Borrowing costs	6.870	5.617
Total	174.479	125.927

NOTE 23 - TAX ASSETS AND LIABILITIES

Tax expenses for the year ended at 31 December 2011 and 2010 are as follows:

	31 December 2011	31 December 2010
Income tax expense for the period	(18.796)	(14.813)
Deferred tax (expense)/income, net	(3.465)	957
Taxes on income	(22.261)	(13.856)

AKSA AKRİLİK KİMYA SANAYİİ A.Ş.

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2011**

(Amounts expressed in thousands of Turkish Lira (“TL”) unless otherwise indicated.)

NOTE 23 - TAX ASSETS AND LIABILITIES (Continued)

Deferred Income Tax Assets and Liabilities

The breakdown of cumulative temporary differences and deferred income tax assets and liabilities provided using enacted tax rates are as follows:

	Temporary Taxable Differences		Deferred Income Tax Asset/Liability	
	31 December 2011	31 December 2010	31 December 2011	31 December 2010
Property, plant and equipment and intangible assets	(110.410)	(96.353)	(22.082)	(19.271)
Trade payables	(1.880)	(1.337)	(376)	(267)
Other	-	(308)	-	(62)
Deferred income tax liabilities			(22.458)	(19.600)
Employee benefits	14.220	13.168	2.844	2.634
Derivative financial instruments	4.175	5.000	835	1.000
Trade receivables	2.312	6.682	462	1.336
Inventories	2.765	3.663	553	733
Other current liabilities	2.485	1.788	497	358
Other	423	379	85	76
Deferred income tax assets			5.276	6.137
Deferred income tax liabilities, net			(17.182)	(13.463)
Movement for the deferred income tax liabilities for year ended 31 December 2011 and 2010 are as follows:				
			2011	2010
1 January			13.463	14.663
Deferred tax expense/(income) for the period, net			3.465	(957)
Changes in the scope of consolidation (Note 2.1.3)			89	-
Amounts recognised under equity			165	(243)
31 December			17.182	13.463
			31 December 2011	31 December 2010
Taxes on income			18.796	14.813
Amount deducted from Value Added Tax receivables			(18.427)	(10.974)
Taxes on income			369	3.839

AKSA AKRİLİK KİMYA SANAYİİ A.Ş.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2011

(Amounts expressed in thousands of Turkish Lira ("TL") unless otherwise indicated.)

NOTE 23 - TAX ASSETS AND LIABILITIES (Continued)

The reconciliation of tax expenses stated in consolidated income statements for the year ended 31 December 2011 and 2010 are as follows:

	31 December 2011	31 December 2010
Profit before tax	121.728	75.770
Expected tax expense of the Group (%20)	24.346	15.154
Disallowable expenses	4.780	5.134
Research and development incentive	(10.001)	(8.109)
Dividend income	(2.690)	(2.524)
Other	(2.516)	(991)
Tax Effect (%20)	(2.085)	(1.298)
Current period tax expense of the Group	22.261	13.856

NOTE 24 - EARNINGS PER SHARE

Earnings per share disclosed in the consolidated statements of income are determined by dividing the net income by the weighted average number of shares that have been outstanding during the period. The earnings per share calculation for the year ended 31 December 2011 and 2010 as follows

	31 December 2011	31 December 2010
Net income attributable to the equity holders of the parent (TL) (*)	97.049.347	56.718.366
Weighted average number of shares	18.500.000.000	18.500.000.000
Earnings per share (Kr)	0,52	0,31

(*) Amounts expressed in Turkish Lira.

NOTE 25 - RELATED PARTY DISCLOSURES

As of 31 December 2011 and 2010, trade receivables from related parties are as follows:

	31 December 2011	31 December 2010
Ak-Pa Tekstil İhracat Pazarlama A.Ş. (*) (1)	134.552	-
Akkim Kimya San. ve Tic. A.Ş. (2)	2.606	793
Ak-Al Tekstil Sanayii A.Ş. (2)	1	11.196
Aksa Egypt (3)	-	4.540
Other	2	52
Less: Provision of sales discounts (-)	(2.231)	-
Rediscount (-)	(98)	(232)
Total	134.832	16.349

(*) Sales to Ak-Pa comprise of export sales made to third party customers by export register.

(1) Shareholders' subsidiary and Company's financial investment at 2011 (Company's and Akkök's subsidiary at 2010).

(2) Akkök's subsidiary.

(3) Company's subsidiary at 2011 (Company's financial investment at 2010).

AKSA AKRİLİK KİMYA SANAYİİ A.Ş.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2011

(Amounts expressed in thousands of Turkish Lira (“TL”) unless otherwise indicated.)

NOTE 25 - RELATED PARTY DISCLOSURES (Continued)

As of 31 December 2011 and 2010, non-trade receivables from related parties are as follow (presented in “Other Receivables” in the consolidated balance sheet):

	31 December 2011	31 December 2010
Akport Tekirdağ Liman İşletmeleri A.Ş. (*) (2)	-	20.098
Akkök Sanayi Yatırım ve Geliştirme A.Ş. (*) (4)	-	13.146
Akmetem Poliüretan Sanayi ve Ticaret A.Ş. (*) (2)	-	3.519
Total	-	36.763

(*) Due from related parties amounts are related with borrowings that are taken from Eximbank by Ak-Pa and transferred to group companies.

Short term due to related parties is as follows:

	31 December 2011	31 December 2010
Ak-Pa Tekstil İhracat Pazarlama A.Ş. (1)	22.504	-
Akkim Kimya San. ve Tic. A.Ş. (1)	2.898	8.014
Akkök Sanayi Yatırım ve Geliştirme A.Ş. (3)	659	529
Aktek Bilgi İletişim Teknolojisi San. ve Tic. A.Ş. (1)	496	812
Dinkal Sigorta Acenteliği A.Ş. (1)	87	73
Akenerji Elektrik Üretim A.Ş. (1)	13	2.859
Akenerji Doğal Gaz İthalat İhracat ve Toptan Tic. A.Ş. (1)	-	24.637
Other	87	50
Less: Rediscount (-)	(116)	(545)
Total	26.628	36.429

Sales to related parties for the year ended as of 31.12.2011 and 2010 are as follows:

	31 December 2011	31 December 2010
Ak-Pa Tekstil İhracat Pazarlama A.Ş. (**) (1)	634.038	-
Akkim Kimya San. ve Tic. A.Ş. . (1)	36.077	36.093
Ak-Al Tekstil Sanayii A.Ş. . (1)	17.877	32.247
Akenerji Elektrik Üretim A.Ş. . (1)	137	276
Aksa Egypt . (3)	-	44.600
Other	878	394
Total	689.007	113.610

(**) The sales to Ak-pa consist of sales to third parties via Ak-pa.

- (1) Company shareholder’s subsidiary and Company’s financial investment at 2011 (Company and Company shareholder’s subsidiary at 2010)
- (2) Subsidiary of Akkök
- (3) Company’s subsidiary at 2011 (Company’s financial investment at 2010)
- (4) Company’s shareholder

AKSA AKRİLİK KİMYA SANAYİİ A.Ş.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2011

(Amounts expressed in thousands of Turkish Lira ("TL") unless otherwise indicated.)

NOTE 25 - RELATED PARTY DISCLOSURES (Continued)

Product and service purchases from related parties as of 31.12.2011 and 2010 are as follows:

	31 December 2011	31 December 2010
Akkim Kimya San. ve Tic. A.Ş. (2)	36.252	60.039
Akkök Sanayi Yatırım ve Geliştirme A.Ş. (4)	9.736	6.248
Aktek Bilgi İşlem Tekn. San.ve Tic. A.Ş. (2)	7.009	4.723
Ak-Pa Tekstil İhracat Pazarlama A.Ş. (1)	6.251	-
Dinkal Sigorta Acenteliği A.Ş. (2)	2.386	1.552
Ak Havacılık ve Ulaştırma Hizmetleri A.Ş. (2)	1.033	1.080
Ak-Al Tekstil Sanayii A.Ş. (2)	754	1.041
Ak-Han Bakım Yönt. Serv. Hizm. Güven. Malz. A.Ş. (2)	603	488
Akdepo Lojistik ve Dış Ticaret A.Ş. (2)	501	-
Akenerji Elektrik Üretim A.Ş. (2)	136	901
Akenerji Doğal Gaz İthalat İhracat ve Toptan Tic. A.Ş (2)	-	24.637
Total	64.661	100.709

Purchases from related parties consist of fibers, energy, chemicals, service procurement, consulting and rent expenses.

The Company defined its key management personnel as member of action committee and board of directors, benefits provided to these key management personnel as of 31 December 2011 and 2010 are as follows:

	31 December 2011	31 December 2010
Salary and other short term employee benefits	7.049	4.022
Provision for employee termination benefit	38	22
Providing benefits after working period	-	-
Other long term benefits	-	-
Share based payments	-	-
Total	7.087	4.044

- (1) Company shareholder's subsidiary and Company's financial investment at 2011 (Company and Company shareholder's subsidiary at 2010)
- (2) Subsidiary of Akkök
- (3) Company's subsidiary at 2011 (Company's financial investment at 2010)

NOTE 26 - FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT

Financial risk factors

The Groups principal financial instruments are cash and cash equivalents, trade receivables and financial liabilities. The main purpose of these financial instruments is to raise finance for the Group's operations. The Group has various other financial instruments such as trade debtors and trade creditors, which arise directly from its operations. The main risks arising from the Group's financial instruments are liquidity risk, foreign currency risk and credit risk. The Group management reviews and agrees policies for managing each of the risks as summarized below.

AKSA AKRİLİK KİMYA SANAYİİ A.Ş.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2011

(Amounts expressed in thousands of Turkish Lira ("TL") unless otherwise indicated.)

NOTE 26 - FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT (Continued)

Credit risk

Credit risk is the risk that one party to a financial instrument will fail to discharge an obligation and cause the other party to incur a financial loss. The Group attempts to control credit risk by monitoring credit exposures, limiting transactions with specific counterparties, and continually assessing the creditworthiness of the counterparties. It is the Group policy that all customers who wish to trade on credit terms are subject to credit screening procedures and the Group also obtains collaterals from customers when appropriate. In addition, receivable balances are monitored on an ongoing basis with the result that the Group's exposure to bad debts is not significant. Trade receivables are evaluated by management based on their past experiences and current economic condition, and are presented in financial statements net of provision for doubtful receivables (Note 7).

Trade Receivable Aging Analysis

Aging of the receivables which are overdue but not impaired is as follows:

31 December 2011	Trade Receivables
1-30 days overdue	12.690
1-3 months overdue	10.963
3-12 months overdue	2.201
More than 12 months overdue	131
Total (*)	25.985

Secured with guarantees **21.530**

(*) Overdue trade receivables amounting to TL 18.634 has been collected in the period between the balance sheet date and the date of publication of these financial statements.

31 December 2010	Trade Receivables
1-30 days overdue	5.336
1-3 months overdue	681
3-12 months overdue	570
More than 12 months overdue	1.557
Total	8.144

Secured with guarantees **4.630**

AKSA AKRİLİK KİMYA SANAYİİ A.Ş.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2011

(Amounts expressed in thousands of Turkish Lira (“TL”) unless otherwise indicated.)

NOTE 26 - FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT (Continued)

As of 31 December 2011 amounts carried in the balance sheet reflect maximum credit risk of the Group:

31 December 2011	Trade Receivables		Other receivables		Deposits at bank	
	Related Parties	Other	Related Parties	Other	Related Parties	Other
Maximum credit risk exposure as of reporting date	134.832	267.538	-	30	-	83.666
- Secured portion of maximum credit risk by guarantees (*)	<i>119.520</i>	<i>229.130</i>	-	-	-	-
Net book value of financial assets either are not due or not impaired	128.577	247.809	-	30	-	83.666
Financial assets with renegotiated conditions (**)	-	13.656	-	-	-	-
Net book value of the expired or not impaired financial assets	6.256	19.729	-	-	-	-
- Secured portion with guarantees	5.706	15.824	-	-	-	-
Net book value of impaired assets	-	2.000	-	-	-	-
- Matured (net book value)	-	42.236	-	-	-	-
- Impairment (-) (Note 7)	-	(40.236)	-	-	-	-
- Secured portion with guarantees	-	(2.000)	-	-	-	-

(*) Guarantees taken from the related parties consist of Ak-Pa’s guarantees received from foreign customers. Therefore export sales that are made through Ak-pa are secured by these guarantees.

(**) As of 31 December 2011, re-structured receivables amount of TL 781 has been collected in subsequent period and TL 11.234 portion of given receivables secured with guarantees.

AKSA AKRİLİK KİMYA SANAYİİ A.Ş.

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2011**

(Amounts expressed in thousands of Turkish Lira (“TL”) unless otherwise indicated.)

NOTE 26 - FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT (Continued)

As of 31 December 2010 amounts carried in the balance sheet reflect maximum credit risk of the Group:

31 December 2010	Trade Receivables		Other receivables		Deposits at bank	
	Related Parties	Other	Related Parties	Other	Related Parties	Other
Maximum credit risk exposure as of reporting date	16.349	316.696	36.763	167	-	63.880
- Secured portion of maximum credit risk by guarantees	4.432	177.908	3.650	-	-	-
Net book value of financial assets either are not due or not impaired	16.062	308.839	36.763	167	-	63.880
Financial assets with renegotiated conditions	-	23.738	-	-	-	-
Net book value of the expired or not impaired financial assets	287	7.857	-	-	-	-
- Secured portion with guarantees	-	4.630	-	-	-	-
Net book value of impaired assets	-	-	-	-	-	-
- Matured (net book value)	-	28.789	-	-	-	-
- Impairment (-)	-	(28.789)	-	-	-	-
- Secured portion with guarantees	-	-	-	-	-	-

AKSA AKRİLİK KİMYA SANAYİİ A.Ş.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2011

(Amounts expressed in thousands of Turkish Lira ("TL") unless otherwise indicated.)

NOTE 26 - FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT (Continued)

Foreign Exchange Risk

The Group is exposed to foreign exchange risk arising from the ownership of foreign currency denominated assets and liabilities in the translation of the Turkish Lira. The exchange rate risk is monitored by the analyzing the foreign currency position. The Group is exposed to foreign exchange risk arising from the ownership of foreign currency denominated assets and liabilities.

Foreign currency position presented in TL is as follows:

	31 December 2011	31 December 2010
Assets	435.426	408.567
Liabilities	(723.383)	(446.155)
Net balance sheet position	(287.957)	(37.588)

Foreign currency position as of 31 December 2011 and 31 December 2010 are as follows:

	31 December 2011			Total
	USD position	EURO position	Other foreign currency position	
Assets:				
Cash and cash equivalents	57.526	1.233	1.133	59.892
Trade receivables	335.236	39.329	57	374.622
Other assets	43	23	846	912
Total assets	392.805	40.585	2.036	435.426
Liabilities:				
Financial liabilities	493.189	-	-	493.189
Trade payables	226.065	2.400	1.528	229.993
Other liabilities	-	52	149	201
Total liabilities	719.254	2.452	1.677	723.383
Net foreign currency position	(326.449)	38.133	359	(287.957)

AKSA AKRİLİK KİMYA SANAYİİ A.Ş.

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2011**

(Amounts expressed in thousands of Turkish Lira (“TL”) unless otherwise indicated.)

**NOTE 26 - FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT
(Continued)**

	31 December 2011			Total
	USD position	EURO position	Other foreign currency position	
Assets:				
Cash and cash equivalents	40.408	1.597	4	42.009
Trade receivables	299.136	31.730	-	330.866
Other assets	33.392	2.270	30	35.692
Total assets	372.936	35.597	34	408.567
Liabilities:				
Financial liabilities	297.011	-	-	297.011
Trade payables	144.415	4.729	-	149.144
Total liabilities	441.426	4.729	-	446.155
Net foreign currency position	(68.490)	30.868	34	(37.588)

The following table demonstrates the sensitivity to possible changes in the net position, on the Group’s balance sheet as of 31 December 2011 and 31 December 2010.

31 December 2011	Appreciation of foreign currency	Depreciation of foreign currency
In case 10% appreciation of USD against TL		
USD net asset/ (liability)	(32.645)	32.645
Amount hedged for USD risk	-	-
USD net effect	(32.645)	32.645
In case 10% appreciation of EUR against TL		
EUR net asset/ (liability)	3.813	(3.813)
Amount hedged for EUR risk	-	-
EUR net effect	3.813	(3.813)

AKSA AKRİLİK KİMYA SANAYİİ A.Ş.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2011

(Amounts expressed in thousands of Turkish Lira ("TL") unless otherwise indicated.)

NOTE 26 - FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT (Continued)

31 December 2010	Appreciation of Foreign currency	Depreciation of Foreign currency
In case 10% appreciation of USD against TL		
USD net asset/liability	(6.849)	6.849
Amount hedged for USD risk	-	-
USD net effect	(6.849)	6.849
In case 10% appreciation of EUR against TL		
EUR net asset/liability	3.087	(3.087)
Amount hedged for EUR risk	-	-
EUR net effect	3.087	(3.087)

Interest Risk

The Group is exposed to interest risk arising from the borrowings interest rate changes. According to balance sheet position of the floating interest rate financial liabilities as of 31 December 2011, other things being constant, if the interest rate depreciate/ appreciate by 1%, profit before tax would increase/decrease TL 31 (31 December 2010: TL 18), capitalized borrowing cost on construction in progress would increase/decrease TL 474 (31 December 2010: TL 194).

31 December 2011 31 December 2010

Fixed interest rate financial instruments

Financial assets

Cash and cash equivalents (Note 4) (*)	60.854	51.711
--	--------	--------

Financial liabilities

USD borrowings	204.974	212.415
TL Borrowings	-	13.554

Floating interest rate financial instruments

Financial assets

Cash and cash equivalents (Note 4) (*)	-	-
--	---	---

Financial liabilities

USD borrowings	288.257	84.596
----------------	---------	--------

(*) Cash and cash equivalents consist of bank deposits with maturity less than three months.

AKSA AKRİLİK KİMYA SANAYİİ A.Ş.

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2011**

(Amounts expressed in thousands of Turkish Lira (“TL”) unless otherwise indicated.)

NOTE 26 - FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT (Continued)

Liquidity risk

Liquidity risk comprises the risks arising from the inability to fund the increase in the assets, the inability to cover the liabilities due and the operations performed in illiquid. In the framework of liquidity risk management, funding sources are being diversified, and sufficient cash and cash equivalents are held.

The breakdown of financial assets and liabilities according to their maturities is disclosed considering from balance sheet date to due date period. Financial assets and liabilities that have no certain due dates are classified in over one year column.

31 December 2011:

Expected or maturities per agreement	Carrying value	Contractual cash flows	Up to 3 months	3-12 months	1-5 years	Over than 5 years
Non-derivative financial liabilities						
Financial liabilities	493.231	557.115	2.335	183.621	229.764	141.395
Trade payables	226.135	228.039	147.964	80.075	-	-
Due to related parties	26.628	26.685	25.447	1.238	-	-
	745.994	811.839	175.746	264.934	229.764	141.395
Derivative financial instruments						
Derivative cash outflow	4.175	4.288	311	1.954	2.023	-

31 December 2010:

Expected or maturities per agreement	Carrying value	Contractual cash flows	Up to 3 months	3-12 months	1-5 years	Over than 5 years
Non-derivative financial liabilities						
Financial liabilities	310.565	324.688	44.947	130.451	149.290	-
Trade payables	175.294	176.505	116.232	60.273	-	-
Due to related parties	36.429	36.975	9.255	27.720	-	-
	522.288	538.168	170.434	218.444	149.290	-
Derivative financial instruments						
Derivative cash outflow	5.000	5.190	375	2.331	2.484	-

AKSA AKRİLİK KİMYA SANAYİİ A.Ş.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2011

(Amounts expressed in thousands of Turkish Lira ("TL") unless otherwise indicated.)

NOTE 26 - FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT (Continued)

Import export information:

Import export for the years ended at 31 December 2011 and 2010 are as follows:

Export

	31 December 2011	31 December 2010
USD	410.522	334.244
EUR	187.053	134.305
Other	12.025	41
Total	609.600	468.590

Import

	31 December 2011	31 December 2010
USD	863.912	632.741
EUR	61.658	45.454
Other	12.324	920
Total	937.894	679.115

Capital risk management

The Group's objectives when managing capital are to safeguard the Group's ability to continue as a going concern in order to provide returns for shareholders and benefits for other stakeholders and maintain an optimal structure to reduce the cost of capital.

In order to maintain or adjust the capital structure, the Group may adjust the amount of dividends paid to shareholders, return capital to shareholders, issue new shares or sell assets to reduce debt.

Consistent with others in the industry, the Group monitors capital on the basis of the gearing ratio. This ratio is calculated as net debt divided by total capital. Net debt is calculated as total borrowings (including financial liabilities, trade payables and due to related parties, as shown in the consolidated balance sheet) less cash and cash equivalents. Total capital is calculated as equity, as shown in the consolidated balance sheet, plus net debt.

AKSA AKRİLİK KİMYA SANAYİİ A.Ş.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2011

(Amounts expressed in thousands of Turkish Lira ("TL") unless otherwise indicated.)

NOTE 26 - FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT (Continued)

The ratio of net debt to equity is as follows:

	31 December 2011	31 December 2010
Total liabilities	745.994	522.288
Less: Cash and cash equivalents (Note 4)	(85.106)	(64.499)
Net debt	660.888	457.789
Total shareholders' equity	850.947	775.765
Total capital	1.511.835	1.233.554
Debt/equity ratio	%44	%37

NOTE 27 - FINANCIAL INSTRUMENTS

Fair value estimation

Fair value is the amount at which a financial instrument could be exchanged in a current transaction between willing parties, other than in a forced sale or liquidation, and is best evidenced by a quoted market price, if one exists.

The estimated fair values of financial instruments have been determined by the Group, using available market information and appropriate valuation methodologies. However, judgment is necessarily required to interpret market data to estimate the fair value. Accordingly, the estimates presented herein are not necessarily indicative of the amounts the Group could realise in a current market exchange.

The following methods and assumptions are used to estimate the fair value of the financial instruments:

Financial assets

Monetary assets and liabilities denominated in foreign currencies have been translated at the exchange rates prevailing at the balance sheet dates. These balances are anticipated to close their book value.

The carrying values of significant portion of cash and cash equivalents are assumed to approximate to their fair value due to their short-term nature.

The carrying values of trade receivables are assumed to approximate to their fair value.

AKSA AKRİLİK KİMYA SANAYİİ A.Ş.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2011

(Amounts expressed in thousands of Turkish Lira (“TL”) unless otherwise indicated.)

NOTE 27 - FINANCIAL INSTRUMENTS (Continued)

Financial liabilities

The fair values of short term borrowings and trade payables are assumed to approximate to their carrying values due to their short-term nature.

The estimated fair value of demand deposits expresses the amount to be paid at the moment of withdrawal. The fair value of the overnight deposits indicates the book value. The estimated fair value of the fixed interest deposits is determined by calculating the discounted cash flows, using the market interest rates applied to similar loan and other debts. In case where the maturities are short, the carrying values are assumed to reflect the fair values (Note 6).

Fair Value Estimation:

Effective 1 January 2010, the group adopted the amendment to IFRS 7 for financial instruments that are measured in the balance sheet at fair value, this requires disclosure of fair value measurements by level of the following fair value measurement hierarchy:

- Level 1: Quoted prices (unadjusted) in active markets for identical assets or liabilities.
- Level 2: Inputs other than quoted prices included within level 1 that are observable for the asset or liability, either directly (that is, as prices) or indirectly (that is, derived from prices);
- Level 3 Inputs for the asset or liability that is not based on observable market data (that is, unobservable inputs).

31 December 2011

	Level 1	Level 2	Level 3
Hedging derivative financial instruments	-	4.175	-
Total Liabilities	-	4.175	-

31 December 2010

	Level 1	Level 2	Level 3
Hedging derivative financial instruments	-	5.000	-
Total Liabilities	-	5.000	-

The fair value of financial instruments that are not traded in an active market is determined by using valuation techniques. These valuation techniques maximise the use of observable market data where it is available and rely as little as possible on entity specific estimates. If all significant inputs required to fair value an instruments are observable, the instrument is included in level 2.

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2011**

(Amounts expressed in thousands of Turkish Lira (“TL”) unless otherwise indicated.)

**NOTE 28 - SUBSEQUENT EVENTS AND OTHER ISSUES THAT MATERIALLY AFFECT
THE FINANCIAL STATEMENTS AND NEED TO BE EXPLAINED TO ENSURE
THE FINANCIAL STATEMENTS ARE CLEAR, INTERPRETABLE AND
UNDERSTANDABLE**

1. In accordance with sub-paragraph (b), paragraph 3, Article 19 and Article 20 of Corporate Tax Law No. 5520; Article 19.2.2 of Corporate Tax General Communiqué Serial 1, dated 3 April 2007, of the Ministry of Finance; the Communiqué of the Ministry of Finance and Ministry of Industry and Trade on Principles and Procedures for Partial Spin-off Transactions of Joint Stock Companies and Limited Liability Companies that was published in the Official Gazette No. 25231, dated 16 September 2003; and Decision No. 39/1065, dated 25 November 2011, of the Capital Markets Board, partial spin-off of Aksa Akrilik Kimya Sanayii Anonim Şirketi to establish a new joint stock company comprising the carbon fiber operations as a capital in kind was approved. Transaction was also approved at the extraordinary general assembly held on 28 December 2011.

Following the completion of partial spin-off transactions, Aksa Karbon Elyaf Sanayi A.Ş. was established on 2 January 2012 and with the objective to specifically focus on production and worldwide marketing of carbon fiber and carbon fiber-based high technology materials.

A Joint Enterprise Agreement was executed by between Aksa Akrilik Kimya Sanayii A.Ş. and Dow Europe Holding B.V. on 20 December 2011 with the intention to establish integrated manufacture facilities containing whole value chain, presenting a wide product range and technical service solutions to the carbon fiber based composite industry, and developing activities on the international level by evaluating all alternatives by means of the new company 99,99% of which is owned by Aksa Akrilik Kimya Sanayii A.Ş..

Following the completion of relevant preliminary conditions, it is planned that shares corresponding to 50% of total shares in Aksa Karbon Elyaf Sanayi A.Ş., whose Enterprise Value is USD 275,000,000 and total share value is USD 185,000,000, will be transferred to Dow Europe Holding B.V. within 2012. The share transfer value will be adjusted taking into account the closing balance sheet date at the date of the partnership in Aksa Karbon Elyaf Sanayi A.Ş..

2. The Company resolved that it shall participate in capital increase for Aksa Karbon Elyaf Sanayi A.Ş., established on 2 January 2012, in March 2012 with TL 48,999,996, TL 35,035,673 of which shall be paid in cash and the remaining TL 13,964,323 shall be covered by adding other capital reserves account to the capital of Aksa Karbon Elyaf Sanayi Anonim Şirketi and that non-paid up shares to be issued as a result of the non-cash portion of the capital increase.

.....